View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2014	Feb. 28, 2015	Jun. 30, 2014
Document Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	GEVO
Entity Registrant Name	GEVO, INC.
Entity Central Index Key	0001392380
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		138,090,748
Entity Public Float			$ 59.4

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 6,359	$ 24,625
Accounts receivable	2,361	1,358
Inventories	4,292	3,581
Prepaid expenses and other current assets	732	1,163
Total current assets	13,744	30,727
Property, plant and equipment, net	81,240	83,475
Debt issue costs, net	530	801
Restricted deposits	2,611
Deposits and other assets	803	1,352
Total assets	98,928	116,355
Current liabilities:
Accounts payable and accrued liabilities	8,588	13,030
Current portion of secured debt, net of $31 and $492 discount at December 31, 2014 and 2013, respectively	288	788
Derivative warrant liability	3,114	7,243
Other current liabilities	35
Total current liabilities	12,025	21,061
Long-term portion of secured debt, net of $18 and $450 discount at December 31, 2014 and 2013, respectively	485	9,339
2017 notes recorded at fair value	25,460
2022 notes, net of $13,221 and $15,869 discount at December 31, 2014 and 2013, respectively	13,679	14,501
Other long-term liabilities	315	479
Total liabilities	51,964	45,380
Commitments and Contingencies
Stockholders' Equity
Preferred stock, $0.01 par value per share; 10,000,000 shares authorized; none issued and outstanding at December 31, 2014 and 2013
Common stock, $0.01 par value per share; 250,000,000 authorized; 99,628,054 and 68,492,894 shares issued and outstanding at December 31, 2014 and 2013, respectively	996	685
Additional paid-in capital	349,266	332,443
Deficit accumulated	(303,298)	(262,153)
Total stockholders' equity	46,964	70,975
Total liabilities and stockholders' equity	$ 98,928	$ 116,355

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock shares issued	99,628,054	68,492,894
Common stock, shares outstanding	99,628,054	68,492,894
Short Term Secured Debt
Debt, discount	$ 31	$ 492
Long Term Secured Debt
Debt, discount	18	450
Long Term Convertible Debt
Debt, discount	$ 13,221	$ 15,869

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue and cost of goods sold
Hydrocarbon revenue	$ 3,949	$ 2,157	$ 650
Grant and other revenue	768	2,722	2,818
Total revenues	28,266	8,224	24,385
Cost of goods sold	35,582	14,522	31,492
Gross loss	(7,316)	(9,689)	(8,025)
Operating expenses
Research and development	14,120	20,179	19,431
Selling, general and administrative	18,341	25,548	43,981
Other operating expenses		99
Total operating expenses	32,461	45,826	63,412
Loss from operations	(39,777)	(55,515)	(71,437)
Other (expense) income
Interest expense	(8,255)	(9,301)	(6,338)
Interest expense - debt issuance costs	(3,769)
Loss on conversion of debt		(2,038)
Gain from change in fair value of embedded derivative of the 2022 Notes	3,470	3,114	17,000
Gain (loss) from change in fair value of derivative warrant liability	6,530	(3,195)
Gain from change in fair value of 2017 Notes	648
Other income	8	129	63
Total other expense	(1,368)	(11,291)	10,725
Net loss	$ (41,145)	$ (66,806)	$ (60,712)
Net loss per common share - basic and diluted	$ (0.51)	$ (1.48)	$ (1.86)
Weighted-average number of common shares outstanding - basic and diluted	80,492,432	45,071,618	32,619,091
Ethanol
Revenue and cost of goods sold
Sales	$ 23,549		$ 19,908
Corn
Revenue and cost of goods sold
Sales		$ 3,345	1,009
Cost of goods sold		$ 3,391	$ 918

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Deficit Accumulated
Beginning Balance at Dec. 31, 2011	$ 92,137	$ 264	$ 226,508	$ (134,635)
Beginning Balance (in shares) at Dec. 31, 2011		26,382,058
Issuance of common stock, net	57,430	$ 125	57,305
Issuance of common stock, net (in shares)		12,500,000
Issuance of common stock upon exercise of stock options, warrants and pursuant to an employee stock purchase plan	877	$ 7	870
Issuance of common stock upon exercise of stock options, warrants and pursuant to an employee stock purchase plan (in shares)		654,047
Issuance of restricted stock		$ 2	(2)
Issuance of restricted stock (in shares)		232,732
Issuance of warrants in conjunction with secured debt	120		120
Cancellation of restricted stock		$ (2)	2
Cancellation of restricted stock (in shares)		(162,169)
Non-cash stock-based compensation	7,979		7,979
Net loss	(60,712)			(60,712)
Ending Balance at Dec. 31, 2012	$ 97,831	$ 396	292,782	(195,347)
Ending Balance (in shares) at Dec. 31, 2012		39,606,668
Issuance of common stock, net (in shares)	21,303,750
Issuance of restricted stock		$ 12	(12)
Issuance of restricted stock (in shares)		1,170,775
Cancellation of restricted stock		$ (2)	2
Cancellation of restricted stock (in shares)		(237,795)
Issuance of common stock for services, upon exercise of stock options and pursuant to an employee stock purchase plan	$ 745	$ 5	740
Issuance of common stock for services, upon exercise of stock options and pursuant to an employee stock purchase plan (in shares)		512,113
Non-cash stock-based compensation	3,911		3,911
Issuance of common stock, net of issue costs and warrants	22,331	$ 213	22,118
Issuance of common stock, net of issue costs and warrants (in shares)		21,303,750
Modification of warrants	179		179
Issuance of common stock upon conversion of debt	12,784	$ 61	12,723
Issuance of common stock upon conversion of debt (in shares)		6,137,383
Net loss	(66,806)			(66,806)
Ending Balance at Dec. 31, 2013	70,975	$ 685	332,443	(262,153)
Ending Balance (in shares) at Dec. 31, 2013		68,492,894
Issuance of restricted stock		$ 11	(11)
Issuance of restricted stock (in shares)		1,138,081
Cancellation of restricted stock		$ (1)	1
Cancellation of restricted stock (in shares)		(66,042)
Issuance of common stock for services, upon exercise of stock options and pursuant to an employee stock purchase plan	51	$ 1	50
Issuance of common stock for services, upon exercise of stock options and pursuant to an employee stock purchase plan (in shares)		63,121
Non-cash stock-based compensation	2,860		2,860
Issuance of common stock, net of issue costs and warrants	14,223	$ 300	13,923
Issuance of common stock, net of issue costs and warrants (in shares)		30,000,000
Net loss	(41,145)			(41,145)
Ending Balance at Dec. 31, 2014	$ 46,964	$ 996	$ 349,266	$ (303,298)
Ending Balance (in shares) at Dec. 31, 2014		99,628,054

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Activities
Net loss	$ (41,145)	$ (66,806)	$ (60,712)
Adjustments to reconcile net loss to net cash used in operating activities:
(Gain) loss from change in fair value of derivative warrant liability	(6,530)	3,195
Gain from change in fair value of embedded derivative of the 2022 Notes	(3,470)	(3,114)	(17,000)
Gain from change in fair value of 2017 Notes	(648)
Non-cash stock-based compensation	2,860	3,911	7,979
Depreciation and amortization	4,880	3,393	3,313
Non-cash interest expense	7,860	4,719	2,207
Loss on conversion of debt		2,038
Loss (gain) from change in fair value of derivatives		259	(445)
Other non-cash expenses	66	991	500
Changes in operating assets and liabilities:
Accounts receivable	(1,003)	(660)	2,240
Inventories	(711)	2,148	(2,845)
Prepaid expenses and other current assets	431	345	197
Deposits and other assets		(48)	(149)
Accounts payable, accrued expenses, and long-term liabilities	(1,580)	2,581	(3,343)
Net cash used in operating activities	(38,990)	(47,048)	(68,058)
Investing Activities
Acquisitions of property, plant and equipment	(4,894)	(9,806)	(52,432)
Restricted deposits	(2,611)		40
Proceeds from sales tax refund		2,006
Other		125	(647)
Net cash used in investing activities	(7,505)	(7,675)	(53,039)
Financing Activities
Payments on secured debt	(9,824)	(14,529)	(10,406)
Debt and equity offering costs	(5,873)	(1,711)	(5,876)
Proceeds from issuance of common stock upon exercise of stock options and employee stock purchase plan	19	262	877
Proceeds from issuance of common stock and common stock warrants	18,000	28,761	61,875
Proceeds from issuance of 2017 Notes	25,907
Proceeds from issuance of convertible debt, net			42,300
Proceeds from issuance of secured debt			5,000
Deposit on secured debt and other		(179)	(154)
Net cash provided by financing activities	28,229	12,604	93,616
Net (decrease) in cash and cash equivalents	(18,266)	(42,119)	(27,481)
Cash and cash equivalents
Beginning of year	24,625	66,744	94,225
Ending of year	6,359	24,625	66,744
Supplemental disclosures of cash and non-cash investing and financing transactions
Conversion of convertible debt to common stock		12,784
Cash paid for interest, net of interest capitalized	4,213	4,463	4,307
Interest Expense Capitalized into 2017 Notes	201
Non-cash purchase of property, plant and equipment	108	2,453	390
Accrued offering costs		671
Issuance of common stock for services	31	483
Issuance of common stock warrants	$ 2,400	4,048
Modification of warrants		$ 179
Warrants issued with secured debt			$ 120

Nature of Business and Financial Condition	12 Months Ended
Nature of Business and Financial Condition	Dec. 31, 2014
Accounting Policies [Abstract]
Nature of Business and Financial Condition	1. Nature of Business and Financial Condition Nature of Business. Gevo, Inc. (“Gevo” or the “Company,” which, unless otherwise indicated, refers to Gevo, Inc. and its subsidiaries) is a renewable chemicals and next generation biofuels company focused on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Gevo, Inc. was incorporated in Delaware on June 9, 2005. Gevo, Inc. formed Gevo Development, LLC (“Gevo Development”) in September 2009 to finance and develop biorefineries through joint venture, licensing arrangements, tolling arrangements or direct acquisition (see Note 13 for more information on Gevo Development). Gevo Development became a wholly-owned subsidiary of the Company in September 2010. Gevo Development purchased Agri-Energy, LLC (“Agri-Energy”) in September 2010. Through May 2012, Agri-Energy, a wholly-owned subsidiary of Gevo Development, was engaged in the business of producing and selling ethanol and related products produced at its plant located in Luverne, Minnesota (the “Agri-Energy Facility”). The Company commenced the retrofit of the Agri-Energy Facility in 2011 and commenced initial startup operations for the production of isobutanol at this facility in May 2012. In September 2012, the Company made the strategic decision to pause isobutanol production at the Agri-Energy Facility to focus on optimizing specific parts of the process to further enhance isobutanol production rates. In 2013, the Company modified the Agri-Energy Facility in order to increase the isobutanol production rate. In June 2013, the Company resumed the limited production of isobutanol, operating one fermenter and one Gevo Integrated Fermentation Technology^® (“GIFT^®”) separation system in order to (i) verify that the modifications had significantly reduced the previously identified infections, (ii) demonstrate that its biocatalyst performs in the one million liter fermenters at the Agri-Energy Facility, and (iii) confirm GIFT^® efficacy at commercial scale at the Agri-Energy Facility. In August 2013, the Company expanded production capacity at the Agri-Energy Facility by adding a second fermenter and second GIFT^® system to further verify its results with a second configuration of equipment. In October 2013, the Company began commissioning the Agri-Energy Facility on corn mash to test isobutanol production run rates and to optimize biocatalyst production, fermentation separation and water management systems. In March 2014, the Company decided to leverage the flexibility of its GIFT^® technology and make further modifications the Agri-Energy Facility which it believed would enable the simultaneous production of isobutanol and ethanol. In July 2014, the Company began more consistent co-production of isobutanol and ethanol at the Agri-Energy Facility, with one fermenter utilized for isobutanol production and three fermenters utilized for ethanol production. In line with the Company’s strategy to maximize asset utilization and site cash flows, the Company believes that this configuration of the plant should allow it to continue to optimize its isobutanol technology at a commercial scale, while taking advantage of potentially superior ethanol contribution margins. As of December 31, 2014, the Company continues to engage in research and development, business development, business and financial planning, and to optimize operations for isobutanol and ethanol production at the Agri-Energy Facility and raise capital. Ultimately, the Company believes that the attainment of profitable operations is dependent upon future events, including (i) completing its development activities resulting in commercial production and sales of isobutanol or isobutanol-derived products and/or technology, (ii) obtaining adequate financing to complete its development activities, (iii) obtaining adequate financing to build out further isobutanol production capacity, (iv) gaining market acceptance and demand for its products and services, and attracting and (v) retaining qualified personnel. The Company has primarily derived revenue from the sale of ethanol, distiller’s grains and other related products produced as part of the ethanol production process at the Agri-Energy Facility. The production of ethanol alone is not the Company’s intended business and its future strategy is expected to depend on its ability to produce and market isobutanol and products derived from isobutanol. Given that the production of ethanol alone is not the Company’s intended business, and the Company is only beginning to achieve more consistent production and revenue from the sale of isobutanol, the historical operating results of Agri-Energy may not be indicative of future operating results for Agri-Energy or Gevo. Financial Condition. For the year ended December 31, 2014, the Company incurred a consolidated net loss of $41.1 million and had an accumulated deficit of $303.3 million. The Company’s cash and cash equivalents at December 31, 2014 totaled $6.4 million which is primarily being used for the following: (i) operating activities and completion of the side-by-side configuration of the Agri-Energy Facility; ii) operating activities at its corporate headquarters in Colorado, including research and development work; (iii) capital improvements primarily associated with its Agri-Energy Facility; (iv) costs associated with optimizing isobutanol production technology; (v) costs associated with the ongoing litigation with Butamax Advanced Biofuels LLC (“Butamax”), a joint venture vetween BP p.l.c. (“BP”) and E. I. du Pont de Nemours and Company (“DuPont”); and (vi) debt service obligations. The Company expects to incur future net losses as it continues to fund the development and commercialization of its product candidates. The Company’s transition to profitability is dependent upon, among other things, the successful development and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability or positive cash flows, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, the Company may seek additional capital through arrangements with strategic partners or from other sources, it may seek to restructure its secured debt and it will continue to address its cost structure. Notwithstanding, there can be no assurance that the Company will be able to raise additional funds, or achieve or sustain profitability or positive cash flows from operations. Based on the Company’s operating plan, existing working capital at December 31, 2014 was not sufficient to meet the cash requirements to fund planned operations through December 31, 2015 without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern at December 31, 2014. The Company’s inability to continue as a going concern may potentially affect the Company’s rights and obligations under its Senior Secured Debt, Secured Debt and Convertible Notes. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. See Note 8 for information on the Company’s debt obligations and see Note 20 for information on the Company’s issuance of common stock units subsequent to December 31, 2014. Despite the Company’s continued success in meeting isobutanol fermentation targets, producing isobutanol and ethanol simultaneously, and its progress toward achieving breakeven earnings before interest, taxes, depreciation and amortization (EBITDA) at the Agri-Energy Facility, the Company continues to face significant expenses related to its ongoing litigation with Butamax. While the U.S. Supreme Court recently ruled in the Company’s favor and overturned an earlier Federal Circuit Court of Appeals ruling on the interpretation of key claims related to certain patents, trials related to other patents were recently scheduled for August 2015 and April 2016 and the Company expects to incur significant costs preparing for and participating in these upcoming trials. The Company continues to believe that the Butamax complaints are without merit. However, if it is unable to raise the significant funds that will be required for it to continue to defend intellectual property rights, the Company could be forced to change its business strategy which may include one or more of the following: (i) terminating the research and development, manufacture, sale and use of products that include the subject intellectual property; (ii) conducting research and development and manufacturing any products that include the subject intellectual property outside of the U.S.; (iii) shifting its focus to the production of ethanol and/or the development of hydrocarbon products, including those that can be produced from ethanol; or (iv) pursuing strategic alternatives, including the monetization of some or all of the Company’s assets, in order to maximize stockholder value.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Principles of Consolidation. The consolidated financial statements of Gevo include the accounts of its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

Concentrations of Credit Risk. The Company’s financial instruments that are exposed to concentrations of credit risk consist of cash and cash equivalents in excess of the federally insured limits. The Company’s cash and cash equivalents are deposited with high credit quality financial institutions and are primarily in demand deposit accounts.

Cash and Cash Equivalents. The Company maintains its cash and cash equivalents in highly liquid interest bearing money market accounts or non-interest bearing checking accounts. The Company considers all highly liquid investments purchased with a remaining maturity of three months or less at the date of acquisition to be cash equivalents.

Accounts Receivable. The Company records receivables for products shipped and services provided but for which payment has not yet been received. As of December 31, 2014 and 2013, no allowance for doubtful accounts has been recorded, based upon the expected full collection of the accounts receivable.

Inventories. Inventory is recorded at the lower of cost or market value and cost of goods sold is determined by the first-in, first-out method. Ethanol and isobutanol inventory cost consists of the applicable share of raw material, direct labor and manufacturing overhead costs.

Restricted Deposits. The Company maintains a restricted deposit related to the 2017 Notes (defined below) that is equivalent to ten percent of the principal balance.

Derivative Instruments. The Company evaluates its contracts for potential derivatives. See Note 6 for a description of the Company’s accounting for embedded derivatives and Note 7 for a description of the Company’s derivative warrant liability.

Since the acquisition of Agri-Energy in September 2010, the Company’s activities expose it to a variety of market risks, including the effects of changes in commodity prices for corn. These financial exposures are monitored and have been managed by the Company generally through derivative instruments, including forward purchase contracts and exchange traded futures contracts, as an integral part of its overall risk management program. The Company’s risk management program focuses on the unpredictability of financial and commodities markets and seeks to reduce the potentially adverse effects that the volatility of these markets may have on its operating results.

Historically, the Company has followed a policy of using exchange-traded futures contracts as a means of managing exposure to changes in corn prices. Exchange-traded futures contracts, if any, are valued at fair value and are recorded as a derivative asset or liability in the consolidated balance sheets and changes in fair value are recorded in cost of goods sold in the consolidated statements of operations. As of December 31, 2014 and 2013, the Company did not have any exchange-traded futures contracts.

Forward purchase contracts are recorded at fair value unless a company elects to use the “normal purchases and normal sales scope exception” guidance of GAAP. To qualify for the normal purchases and normal sales scope exception, a contract must be appropriately designated and must provide for the purchase or sale of physical commodities in quantities that are expected to be used or sold over a reasonable period of time in the normal course of operations. During the years ended December 31, 2014 and 2013, the Company did not have any forward purchase contracts; therefore, election of the normal purchase and normal sales scope exception was not applicable. While the forward purchase contracts were not material at December 31, 2012, they were recorded at their fair value. Changes in the fair value of forward purchase contracts are recorded in cost of goods sold in the consolidated statements of operations.

The foregoing derivatives do not include any credit risk related contingent features, the Company has not entered into these derivative financial instruments for trading or speculative purposes, and the Company has not designated any of its derivatives as hedges for financial accounting purposes. At December 31, 2014 and 2013, the Company did not have any exchange-traded futures contracts or forward purchase contracts and, as such, did not hold any cash in margin deposit accounts.

The Company records realized and unrealized gains or losses on its derivative instruments as a component of cost of goods sold in the consolidated statements of operations.

The following table summarizes the realized and unrealized gains/ (losses) of the Company’s derivative instruments (in thousands).

	Year Ended December 31,
	2014		2013			2012
Realized Gain / (Losses)
Exchange-traded futures contracts	$	-	$	642		$	(375	)

Unrealized Gain / (Losses)
Exchange-traded futures contracts		-		(271	)		457
Forward purchase contracts		-		12			(12	)

Property, Plant and Equipment. Property, plant and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the assets’ estimated useful lives. Leasehold improvements are amortized over the term of the lease agreement or the service lives of the improvements, whichever is shorter. Assets under construction are depreciated when they are placed into service. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized.

The Company capitalizes interest incurred for capital projects at its Agri-Energy Facility during the period of construction through the date such projects become substantially complete. As of December 31, 2014, the Company had capitalized interest of $1.8 million.

Impairment of Property, Plant and Equipment. The Company’s property, plant and equipment consist primarily of assets associated with the acquisition and retrofit of the Agri-Energy Facility. The Company assesses impairment of property, plant and equipment for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate, or legal or regulatory factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; or expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. The carrying amount of a long-lived asset is considered to be impaired if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the assets.

The Company evaluated its Agri-Energy Facility for impairment as of December 31, 2014 and 2013. These evaluations included comparing the carrying amount of the acquisition and retrofit of the Agri-Energy Facility to the estimated undiscounted future cash flows at the Agri-Energy Facility as this represents the lowest level of identifiable cash flows. Significant assumptions included in the estimated undiscounted future cash flows include, among others, estimates of the:

—	sales price of isobutanol and by-products such as dried distiller’s grains;

—	purchase price of corn;

—	production levels of isobutanol;

—	capital and operating costs to produce isobutanol; and

—	estimated useful life of the primary asset.

Factors which can impact these assumptions include, but are not limited to;

—	effectiveness of the Company’s technology to produce isobutanol at targeted margins;

—	demand for isobutanol and oil prices; and

—	harvest levels of corn.

Based upon the Company’s evaluation at December 31, 2014 and 2013, the Company concluded that the estimated undiscounted future cash flows from the Agri-Energy Facility exceeded the carrying value and, as such, these assets were not impaired. Although the Company’s cash flow forecasts are based on assumptions that are consistent with its planned use of the assets, these estimates required significant exercise of judgment and are subject to change in future reporting periods as facts and circumstances change. Additionally, the Company may make changes to its business plan that could result in changes to the expected cash flows. As a result, it is possible that a long- lived asset may be impaired in future reporting periods.

Debt at Fair Value Option. The Company has elected the fair value option for certain long-term debt instruments that qualify for such treatment. See Note 8 for a detailed description of the accounting for the 2017 convertible notes that are accounted for in such manner.

Debt Issue Costs. Debt issue costs are costs incurred in connection with the Company’s debt financings that primarily have been capitalized and are being amortized over the stated maturity period or estimated life of the related debt, using the effective interest method. Debt issue costs for the 2017 convertible notes are expensed in accordance with the Company’s election of the fair value option for such notes.

Revenue Recognition. The Company records revenue from the sale of hydrocarbon products, ethanol and related products, including the sale of corn inventory. The Company recognizes revenue when all of the following criteria are satisfied: persuasive evidence of an arrangement exists; risk of loss and title transfer to the customer; the price is fixed or determinable; and collectability is reasonably assured. Ethanol and related products are generally shipped free on board shipping point. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers. In accordance with the Company’s agreements for the marketing and sale of ethanol and related products, commissions due to marketers were deducted from the gross sales price at the time payment was remitted. Ethanol and related products sales were recorded net of commissions.

Revenue related to government research grants and cooperative agreements is recognized in the period during which the related costs are incurred, provided that the conditions under the awards have been met and only perfunctory obligations are outstanding.

Cost of Goods Sold. Cost of goods sold includes costs incurred in conjunction with the initial startup operations for the production of isobutanol at the Agri-Energy Facility and costs directly associated with the ethanol production process such as costs for direct materials, direct labor and certain plant overhead costs. Costs associated with the initial operations for the production of isobutanol includes costs for direct materials, direct labor, plant utilities, including natural gas, and plant depreciation. Direct materials consist of dextrose for initial production of isobutanol, corn feedstock, denaturant and process chemicals. Direct labor includes compensation of personnel directly involved in production operations at the Agri-Energy Facility. Costs of direct materials for the production of ethanol consist of corn feedstock, denaturant and process chemicals. Direct labor includes compensation of personnel directly involved in the operation of the Agri-Energy Facility. Plant overhead costs primarily consist of plant utilities and plant depreciation. Cost of goods sold is mainly affected by the cost of corn and natural gas. Corn is the most significant raw material cost. The Company purchases natural gas to power steam generation in the production process and to dry the distiller’s grains. The Company historically has entered into forward purchase contracts and exchange-traded futures contracts associated with corn. Accordingly, the Company’s cost of goods sold also includes gains or losses and/or changes in fair value from its forward purchase contracts and exchange-traded futures contracts. As of December 31, 2014 and 2013, the Company did not have any forward purchase contracts or exchange-traded futures contracts.

Patents . All costs related to filing and pursuing patent applications are expensed as incurred as recoverability of such expenditures is uncertain. Patent-related legal expenses incurred are recorded as selling, general and administrative expense, and during the years ended December 31, 2014, 2013 and 2012 were $0.9 million, $2.3 million and $2.7 million, respectively.

Research and Development. Research and development costs are expensed as incurred and are recorded as research and development expense in the consolidated statements of operations. The Company’s research and development costs consist of expenses incurred to identify, develop, and test its technologies for the production of isobutanol and the development of downstream applications thereof. Research and development expense includes personnel costs, consultants and related contract research, facility costs, supplies, depreciation on property, plant and equipment used in development, license fees and milestone payments paid to third parties for use of their intellectual property and patent rights, and other direct and allocated expenses incurred to support the Company’s overall research and development programs.

Income Taxes. Deferred tax assets and liabilities are recognized based on the difference between the carrying amounts of assets and liabilities in the financial statements and their respective tax bases. Deferred tax assets and liabilities are measured using currently enacted tax rates in effect in the years in which those temporary differences are expected to reverse. Deferred tax assets should be reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. At December 31, 2014 and 2013, based upon current facts and circumstances, the Company had recorded a valuation allowance against its deferred tax assets of $119.4 million and $105.0 million, respectively.

Stock-Based Compensation. The Company’s stock-based compensation expense includes expenses associated with share-based awards granted to employees, board members, non-employees and expenses associated with awards under its employee stock purchase plan (“ESPP”). Stock-based compensation expense for all share-based payment awards granted is based on the grant date fair value. The grant date fair value for stock option awards is estimated using the Black-Scholes option pricing model and the grant date fair value for restricted stock awards is based upon the closing price of the Company’s common stock on the date of grant. The Company recognizes compensation costs for share-based payment awards granted to employees net of estimated forfeitures and recognizes stock-based compensation expense for only those awards expected to vest on a straight-line basis over the requisite service period of the award, which is currently the vesting term of up to four years. For performance based restricted stock awards, the Company recognizes expense over the requisite service period. The fair values of share-based awards granted to non-employees are remeasured as the services are performed and the awards vest, and the resulting change in value, if any, is recognized as expense during the period the related services are rendered.

Net Loss Per Share. Basic net loss per share is computed by dividing the net loss attributable to Gevo, Inc. common stockholders for the period by the weighted-average number of common shares outstanding during the period. Diluted earnings per share (“EPS”) includes the dilutive effect of common stock equivalents and is computed using the weighted-average number of common stock and common stock equivalents outstanding during the reporting period. Diluted EPS for the years ending December 31, 2014, 2013 and 2012 excluded common stock equivalents because the effect of their inclusion would be anti-dilutive, or would decrease the reported loss per share.

The following table sets forth securities that could potentially dilute the calculation of diluted earnings per share. This table excludes any shares that could potentially be issued in settlement of make-whole payments associated with the 2017 Notes and the 2022 Notes.

	Year Ended December 31,
	2014		2013		2012
Warrants to purchase common stock		37,563,548		22,563,748		1,229,998
Convertible 2017 notes		22,537,983		-		-
Convertible 2022 notes		4,725,516		4,725,514		7,905,137
Outstanding options to purchase common stock		3,673,539		2,871,563		2,940,352
Unvested restricted common stock		875,265		791,389		183,416
Total		69,375,851		30,952,214		12,258,903

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014‑09”). The objective of ASU 2014-09 is to outline a new, single comprehensive model to use in accounting for revenue arising from contracts with customers. The new revenue recognition model provides a five-step analysis determining when and how revenue is recognized, depicting the transfer of promised goods or services to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. ASU 2014‑09 is effective for fiscal years and interim periods within those years beginning after December 15, 2016. Early adoption is not permitted. The Company is currently evaluating the impact of adopting ASU 2014‑09.

In June 2014, the FASB issued Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (“ASU 2014-10”). The amendments in ASU 2014-10 remove all incremental financial reporting requirements from GAAP for development stage entities, including the removal of Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification®. ASU 2014-10 is effective for the first annual period beginning after December 15, 2014. The revised consolidation standards are effective one year later, in annual periods beginning after December 15, 2015. Early adoption is permitted and the Company adopted ASU 2014-10 in the third quarter of 2014 which consisted principally of removing inception to date information on the Company’s statements of operations, equity and cash flows as well as other inception to date disclosures in the notes to its consolidated financial statements.

Inventories

12 Months Ended

Dec. 31, 2014

Inventory Disclosure [Abstract]

Inventories

3. Inventories

The following table sets forth the components of the Company’s inventory balances (in thousands).

	December 31,
	2014		2013
Raw materials
Corn	$	1,369	$	1,456
Enzymes and other inputs		354		514
Finished goods		515		192
Work in process		610		224
Spare parts		1,444		1,195

Total inventories	$	4,292	$	3,581

Work in process inventory includes unfinished jet fuel and isobutanol inventory.

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2014

Property Plant And Equipment [Abstract]

Property, Plant and Equipment

4. Property, Plant and Equipment

The following table sets forth the Company’s property, plant and equipment by classification (in thousands).

		December 31,
		2014			2013
Construction in progress	-	$	440		$	66,033
Plant machinery and equipment	10 years		13,367			11,009
Site improvements	10 years		7,015			7,007
Retrofit asset	20 years		65,601			-
Lab equipment, furniture and fixtures and vehicles	5 years		6,385			6,303
Demonstration plant	2 years		3,597			3,597
Buildings	10 years		2,543			2,543
Computer, office equipment and software	3 years		1,490			1,437
Leasehold improvements, pilot plant, land and support equipment	2 - 5 years		2,144			2,105
Total property, plant and equipment			102,582			100,034
Less accumulated depreciation and amortization			(21,342	)		(16,559	)

Property, plant and equipment, net		$	81,240		$	83,475

The Retrofit asset, as defined below, was placed in service in the third quarter of 2014 and is being depreciated over 20 years.

Prior to the first quarter of 2014, the Company capitalized interest on its secured debt associated with its qualifying assets, which related to the retrofit of the Agri-Energy Facility (“Retrofit asset”) that was actively being developed. The Company did not capitalize any interest for the year ended December 31, 2014 as there were no qualifying assets which were actively being developed. The Company capitalized $0.2 million and $1.3 million of interest incurred during the years ended December 31, 2013 and 2012, respectively.

As of December 31, 2014 and 2013, the Company has $0.7 million and $0.7 million, respectively, of capital lease assets included in computer, office equipment and software. The Company includes amortization of capital lease assets of $0.1 million during each of the years ended December 31, 2014, 2013 and 2012, as a component of depreciation and amortization in the consolidated statements of cash flows.

The Company recorded $4.9 million, $3.4 million and $3.3 million of depreciation expense for the years ended December 31, 2014, 2013 and 2012, respectively, including $4.0 million, $2.1 million and $2.1 million of depreciation expense in cost of goods sold for the years ended December 31, 2014, 2013 and 2012, respectively.

Accounts Payable and Accrued Liabilities

12 Months Ended

Dec. 31, 2014

Payables And Accruals [Abstract]

Accounts Payable and Accrued Liabilities

5. Accounts Payable and Accrued Liabilities

The following table sets forth the components of the Company’s accounts payable and accrued liabilities in the consolidated balance sheets (in thousands).

	December 31,
	2014		2013
Accounts payable - trade	$	2,639	$	6,460
Accrued legal-related fees		2,944		2,999
Deferred revenue		-		1,000
Accrued employee compensation		801		818
Other accrued liabilities		2,204		1,753

Total accounts payable and accrued liabilities	$	8,588	$	13,030

Embedded Derivatives

12 Months Ended

Dec. 31, 2014

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Embedded Derivatives

6. Embedded Derivatives

In July 2012, the Company issued 7.5% convertible senior notes due 2022 (the “2022 Notes”) which contain the following embedded derivatives: (i) rights to convert into shares of the Company’s common stock, including upon a Fundamental Change (as defined in the indenture governing the 2022 Notes (the “Indenture”)); and (ii) a Coupon Make-Whole Payment (as defined in the Indenture) in the event of a conversion by the holders of the 2022 Notes prior to July 1, 2017. Embedded derivatives are separated from the host contract, the 2022 Notes, and carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument. The Company has concluded that the embedded derivatives within the 2022 Notes meet these criteria and, as such, must be valued separate and apart from the 2022 Notes and recorded at fair value each reporting period.

The Company used a binomial lattice model in order to estimate the fair value of the embedded derivative in the 2022 Notes. A binomial lattice model generates two probable outcomes, whether up or down, arising at each point in time, starting from the date of valuation until the maturity date. A lattice model was initially used to determine if the 2022 Notes would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the 2022 Notes will be converted early if the conversion value is greater than the holding value; and (ii) the 2022 Notes will be called if the holding value is greater than both (a) the Redemption Price (as defined in the Indenture) and (b) the conversion value plus the Coupon Make-Whole Payment at the time. If the 2022 Notes are called, then the holders will maximize their value by finding the optimal decision between (1) redeeming at the Redemption Price and (2) converting the 2022 Notes.

Using this lattice model, the Company valued these embedded derivatives using a “with-and-without method,” where the value of the 2022 Notes including the embedded derivative, is defined as the “with”, and the value of the 2022 Notes excluding the embedded derivative, is defined as the “without”. This method estimates the value of the embedded derivative by looking at the difference in the values between the 2022 Notes with the embedded derivative and the value of the 2022 Notes without the embedded derivative. The lattice model requires the following inputs: (i) price of Gevo common stock; (ii) Conversion Rate (as defined in the Indenture); (iii) Conversion Price (as defined in the Indenture); (iv) maturity date; (v) risk-free interest rate; (vi) estimated stock volatility; and (vii) estimated credit spread for the Company.

The following table sets forth the inputs (Level 2 as defined in Note 18) to the lattice model that were used to value the embedded derivatives.

	December 31,
	2014			2013
Stock price	$	0.32		$	1.43
Conversion Rate		175.6697			175.6697
Conversion Price	$	5.69		$	5.69
Maturity date	July 1, 2022			July 1, 2022
Risk-free interest rate		2.0	%		2.8	%
Estimated stock volatility		87	%		65	%
Estimated credit spread		20	%		33	%

Changes in certain inputs into the lattice model can have a significant impact on changes in the estimated fair value of the embedded derivatives. For example, the estimated fair value of the embedded derivatives will generally decrease with; (i) a decline in the stock price; (ii) decreases in the estimated stock volatility; and (iii) decrease in the estimated credit spread.

The following table sets forth the value of the 2022 Notes with and without the embedded derivatives, and the fair value of the embedded derivatives (in thousands).

	December 31,
	2014		2013
Fair value of 2022 Notes:
With the embedded derivative	$	19,449	$	15,925
Without the embedded derivative		19,449		12,455
Estimated fair value of the embedded derivative	$	-	$	3,470

During the years ended December 31, 2014, 2013 and 2012, the estimated fair value of the embedded derivatives decreased by $3.5 million, $3.1 million and $17.0 million, respectively. The decline in the estimated fair value of the embedded derivatives represents an unrealized gain which has been recorded as gain from change in fair value of embedded derivatives in the consolidated statements of operations. The Company recorded the estimated fair value of the embedded derivative in 2022 notes, net in the consolidated balance sheets.

- Definition

The entire disclosure for hybrid instruments and embedded derivatives, including discussion of the process used in evaluating whether a hybrid instrument in the form of a share constitutes a debt or equity security, and on what basis an embedded derivative was deemed to be separable or inseparable from the host instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 15
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35708913&loc=d3e50883-113970

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 15
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35708913&loc=d3e50896-113970

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 15
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35708913&loc=d3e50876-113970

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 15
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6437212&loc=d3e50806-113969

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 15
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=34750511&loc=d3e48542-113965

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624163-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13495-108611

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Hybrid Instrument
-URI http://asc.fasb.org/extlink&oid=6514950

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Embedded Derivative
-URI http://asc.fasb.org/extlink&oid=6511375

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n)(1),(7))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Derivative Warrant Liability

12 Months Ended

Dec. 31, 2014

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivative Warrant Liability

7. Derivative Warrant Liability

In December 2013, the Company sold 21,303,750 common stock units. Each common stock unit consisted of one share of the Company’s common stock and a warrant to purchase one share of the Company’s common stock (the “2013 Warrants”). The agreement governing the 2013 Warrants includes the following terms:

—

at December 31, 2014, the 2013 Warrants had an exercise price of $1.43 per share, subject to adjustment for certain events, including the issuance of stock dividends on the Company’s common stock and, in certain instances, the issuance of the Company’s common stock or instruments convertible into the Company’s common stock at a price per share less than the exercise price of the 2013 Warrants (as a result of the public offering of common stock units in February 2015, these anti-dilution provisions were triggered and the exercise price of the 2013 Warrants have now decreased to $1.02 per share);

—	the 2013 Warrants have an expiration date of December 16, 2018;

—

a holder of 2013 Warrants may exercise the warrants through a cashless exercise if, and only if, the Company does not have an effective registration statement then available for the issuance of the shares of its common stock. If an effective registration statement is available for the issuance of its common stock a holder may only exercise the 2013 Warrants through a cash exercise;

—

the exercise price and the number and type of securities purchasable upon exercise of the 2013 Warrants are subject to adjustment upon certain corporate events, including certain combinations, consolidations, liquidations, mergers, recapitalizations, reclassifications, reorganizations, stock dividends and stock splits, a sale of all or substantially all of the Company’s assets and certain other events; and

—

in the event of an extraordinary transaction (as defined in the 2013 Warrant Agreement) generally including any merger with or into another entity, sale of all or substantially all of the Company’s assets, tender offer or exchange offer, or reclassification of its common stock, the Company or any successor entity will pay the 2013 Warrant holder, at such holder’s option, exercisable at any time concurrently with or within 30 days after the consummation of the extraordinary transaction, an amount of cash equal to the value of such holder’s warrants as determined in accordance with the Black Scholes option pricing model at the measurement date defined in the 2013 Warrant Agreement.

In August 2014, the Company sold 30,000,000 shares of common stock and warrants to purchase an additional 15,000,000 shares of common stock (the “2014 Warrants”). The agreement governing the 2014 Warrants includes the following terms:

—

at December 31, 2014, the 2014 Warrants have an exercise price of $0.85 per share, subject to adjustment for certain events, including the issuance of stock dividends on the Company’s common stock and, in certain instances, the issuance of the Company’s common stock or instruments convertible into the Company’s common stock at a price per share less than the exercise price of the 2014 Warrants (as a result of the public offering of common stock units in February 2015, these anti-dilution provisions were triggered and the exercise price of the 2014 Warrants have now decreased to $0.64 per share);

—	the 2014 Warrants have an expiration date of August 5, 2019;

—

a holder of 2014 Warrants may exercise the warrants through a cashless exercise if, and only if, the Company does not have an effective registration statement then available for the issuance of the shares of its common stock. If an effective registration statement is available for the issuance of its common stock a holder may only exercise the 2014 Warrants through a cash exercise;

—

the exercise price and the number and type of securities purchasable upon exercise of the 2014 Warrants are subject to adjustment upon certain corporate events, including certain combinations, consolidations, liquidations, mergers, recapitalizations, reclassifications, reorganizations, stock dividends and stock splits, a sale of all or substantially all of the Company’s assets and certain other events; and

—

in the event of an extraordinary transaction (as defined in the 2014 Warrant Agreement) generally including any merger with or into another entity, sale of all or substantially all of the Company’s assets, tender offer or exchange offer, or reclassification of its common stock, the Company or any successor entity will pay the 2014 Warrant holder, at such holder’s option, exercisable at any time concurrently with or within 30 days after the consummation of the extraordinary transaction, an amount of cash equal to the value of such holder’s warrants as determined in accordance with the Black Scholes option pricing model at the measurement date defined in the 2014 Warrant Agreement.

Based on these terms, the Company has determined that the 2013 and 2014 Warrants (together, the “Warrants”) qualify as derivatives and, as such, are presented as derivative warrant liability on the consolidated balance sheets and recorded at fair value each reporting period. The fair value of the Warrants was estimated to be $3.1 million and $7.2 million as of December 31, 2014 and 2013, respectively. During the year ended December 31, 2014, the decrease in the estimated fair value of the Warrants represents an unrealized gain of $6.5 million, which has been recorded as a gain from the change in fair value of derivative warrant liability in the consolidated statements of operations. During the year ended December 31, 2013, the increase in the estimated fair value of the Warrants represents an unrealized loss of $3.2 million, which has been recorded as a loss from the change in fair value of derivative warrant liability in the consolidated statements of operations.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Secured Debt and Convertible Notes

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Senior Secured Debt, Secured Debt and Convertible Notes

8. Senior Secured Debt, Secured Debt and Convertible Notes

Senior Secured Debt

In May 2014, the Company entered into a Term Loan Agreement (the “Loan Agreement”) with the lenders party thereto from time to time (each, a “Lender” and collectively, the “Lenders”) and Whitebox Advisors, LLC, as administrative agent for the Lenders (“Whitebox”), with a maturity date of March 15, 2017, pursuant to which the Lenders committed to provide one or more senior secured term loans to the Company in an aggregate amount of up to approximately $31.1 million on the terms and conditions set forth in the Loan Agreement (collectively, the “Term Loan”). The first advance of the Term Loan in the amount of $22.8 million (the “First Advance”), net of discounts and issue costs of $1.6 million and $1.5 million, respectively, was made to the Company in May 2014. Also in May 2014, the Company and its subsidiaries entered into an Exchange and Purchase Agreement (the “Exchange and Purchase Agreement”) with WB Gevo, Ltd. and the other Lenders party thereto from time to time and Whitebox, in its capacity as administrative agent for the Lenders. Pursuant to the terms of the Exchange and Purchase Agreement, the Lenders were given the right, subject to certain conditions, to exchange all or a portion of the outstanding principal amount of the Term Loan for the Company’s newly created 10% Convertible Senior Secured Notes due March 2017 (the “2017 Notes” and, together with the 2022 Notes, the “Convertible Notes”), which are convertible into shares of the Company’s common stock. While outstanding, the Term Loan bore an interest rate equal to 15% per annum, of which 5% was payable in cash and 10% was payable in kind and capitalized and added to the principal amount of the Term Loan.

In June 2014, the Lenders exchanged all $25.9 million of outstanding principal amount of Term Loan provided in the First Advance for 2017 Notes, together with accrued paid-in-kind interest of $0.2 million. The terms of the 2017 Notes are set forth in an indenture by and among the Company, its subsidiaries in their capacity as guarantors, and Wilmington Savings Fund Society, FSB, as trustee (the “2017 Notes Indenture”). The 2017 Notes will mature on March 15, 2017. The 2017 Notes have a conversion price (the “Conversion Price”) equal to $1.1584 per share or .8633 shares per $1 principal amount of 2017 Notes. Optional prepayment of the 2017 Notes will not be permitted. The 2017 Notes bear interest at a rate equal to 10% per annum, which is payable under certain circumstances, 5% in cash and 5% in kind and capitalized and added to the principal amount of the 2017 Notes (otherwise the full 10% is payable in cash). While the 2017 Notes are outstanding, the Company is required to maintain an interest reserve in an amount equal to 10% of the aggregate outstanding principal amount, to be adjusted on an annual basis. As of December 31, 2014, there was a balance of $2.6 million in the interest reserve account. This amount is classified as restricted deposits.

The 2017 Notes Indenture contains customary affirmative and negative covenants for agreements of this type and events of default, including, restrictions on disposing of certain assets, granting or otherwise allowing the imposition of a lien against certain assets, incurring certain amounts of additional indebtedness, making investments, acquiring or merging with another entity, and making dividends and other restricted payments, unless the Company receives the prior approval of the required holders. The 2017 Notes Indenture also contains limitations on the ability of the holder to assign or otherwise transfer its interest in the 2017 Notes. The 2017 Notes are secured by a lien on substantially all of the assets of the Company and is guaranteed by Agri-Energy and Gevo Development (together, the “Guarantor Subsidiaries” or “Guarantors”). On June 6, 2014, in connection with the issuance of the 2017 Notes, the Company and the Guarantor Subsidiaries entered into a Pledge and Security Agreement in favor of the collateral trustee. The collateral pledged includes substantially all of the assets of the Company and the Guarantor Subsidiaries, including intellectual property and real property. Agri-Energy has also entered into a mortgage with respect to the real property located in Luverne Minnesota.

The holders of the 2017 Notes may, at any time until the close of business on the business day immediately preceding the maturity date, convert the principal amount of the 2017 Notes, or any portion of such principal amount which is at least $1,000, into shares of the Company’s common stock. Upon conversion of the 2017 Notes, the Company will deliver shares of common stock at an initial conversion rate of .8633 shares of common stock per $1 principal amount of the 2017 Notes (equivalent to an initial conversion price of approximately $1.1584 per share of common stock). Such conversion rate is subject to adjustment in certain circumstances, including in the event that there is a dividend or distribution paid on shares of the common stock or a subdivision, combination or reclassification of the common stock. The Company also has the right to increase the conversion rate (i) by any amount for a period of at least 20 business days if the Company’s board of directors determines that such increase would be in the Company’s best interest or (ii) to avoid or diminish any income tax to holders of shares of common stock or rights to purchase shares of common stock in connection with any dividend or distribution. In addition, subject to certain conditions described herein, each holder who exercises its option to voluntarily convert its 2017 Notes will receive a make-whole payment in an amount equal to any unpaid interest that would otherwise have been payable on such 2017 Notes through the maturity date (a “Voluntary Conversion Make-Whole Payment”). Subject to certain limitations, the Company may pay any Voluntary Conversion Make-Whole Payments either in cash or in shares of common stock, at its election.

The Company has the right to require holders of the 2017 Notes to convert all or part of the 2017 Notes into shares of its common stock if the last reported sales price of the common stock over any 10 consecutive trading days equals or exceeds 150% of the applicable conversion price (a “Mandatory Conversion”). Each holder whose 2017 Notes are converted in a Mandatory Conversion will receive a make-whole payment for the converted notes in an amount equal to any unpaid interest that would have otherwise been payable on such 2017 Notes through the maturity date (a “Mandatory Conversion Make-Whole Payment”). Subject to certain limitations, the Company may pay any Mandatory Conversion Make-Whole Payments either in cash or in shares of common stock, at its election. The Company did not require any holders to convert in 2014.

If a fundamental change of the Company occurs, the holders of 2017 Notes may require the Company to repurchase all or a portion of the 2017 Notes at a cash repurchase price equal to 100% of the principal amount of such 2017 Notes, plus accrued and unpaid interest, if any, through, but excluding, the repurchase date, plus a cash make-whole payment for the repurchased 2017 Notes in an amount equal to any unpaid interest that would otherwise have been payable on such convertible 2017 Notes through the maturity date. A fundamental change includes, amongst other things, the Company’s common stock ceasing to be listed on a national securities exchange. See Note 20 for information on the Company’s listing status.

On July 31, 2014, the Company entered into amendments to the 2017 Notes Indenture to, among other things, permit the offering and issuance of the 2014 Warrants and the incurrence of indebtedness by the Company under such warrants.

On January 29, 2015, we commenced a conversion forbearance period in accordance with the terms of the 2017 Notes during which neither the Company nor any holder of the 2017 Notes has the right to convert any principal amount of the 2017 Notes into shares of Common Stock. The conversion forbearance period will terminate when the Company provides notice to the trustee for the 2017 Notes that it has a sufficient number of authorized and unissued shares of Common Stock to permit conversion of all of the outstanding 2017 Notes. If, on June 27, 2015, the conversion forbearance period has not been terminated and we have failed to reserve out of our authorized but unissued shares or shares held in treasury, sufficient shares of Common Stock to provide for the conversion of all of the outstanding 2017 Notes, an event of default under the terms of the 2017 Notes will be triggered. Upon such occurrence, 100% of the principal amount and all accrued and unpaid interest under the 2017 Notes will become immediately due and payable. Any default under the terms of the 2017 Notes could have a material adverse effect on our business, results of operations and financial condition

In connection with the transactions described above, the Company also entered into a Registration Rights Agreement, dated May 9, 2014 (the “Registration Rights Agreement”), pursuant to which the Company filed a registration statement on Form S-3 registering the resale of approximately 17.5 million shares of the Company’s common stock which are issuable under the 2017 Notes. This registration statement was declared effective on July 25, 2014. The Company expects to file additional registration statements on Form S-3 or to amend filings in order to register additional shares of common stock of the Company for sale or resale, as necessary in connection with the 2017 Notes.

The Company has elected the fair value option for accounting of the Term Loan and 2017 Notes in order for management to mitigate income statement volatility caused by measurement basis differences between the embedded instruments and to eliminate complexities of applying certain accounting models. Accordingly, the principal amount of 2017 Notes outstanding at December 31, 2014 of $26.1 million has been recorded at its estimated fair value of $25.5 million and is included in the 2017 Notes recorded at fair value on the consolidated balance sheets at December 31, 2014. Debt issuance costs of $1.5 million were expensed at issuance and debt issuance costs $0.6 million were expensed in subsequent periods in connection with the election of the fair value option. Change in the estimated fair value of the 2017 Notes represents an unrealized gain included in gain from change in fair value of 2017 Notes in the consolidated statement of operations. The fair value of the 2017 Notes at the issuance date were equal to the net proceeds from the loan. During the year ended December 31, 2014, the Company incurred cash interest expense of $1.6 million and capitalized non-cash paid-in-kind interest expense of $0.2 million into the principal amount of 2017 Notes as of December 31, 2014.

The following table sets forth the inputs to the lattice model that were used to value the Term Loan and 2017 Notes for which the fair value option was elected.

	December 31,
	2014
Stock price	$	0.34
Conversion Rate		863.3
Conversion Price	$	1.16
Maturity date	March 15, 2017
Risk-free interest rate		0.80	%
Estimated stock volatility		85.0	%
Estimated credit spread		15.0	%

The following table sets forth information pertaining to the Term Loan and 2017 Notes which is included in the Company’s consolidated balance sheets (in thousands).

	Principal Amount of Term Loans			Principal Amount of 2017 Notes		Change in Estimated Fair Value			Total
Balance - December 31, 2013	$	-		$	-	$	-		$	-
Issuance of Term Loan		25,907			-		-			25,907
Exchange of Term Loan for 2017 Notes		(25,907	)		25,907		-			-
Non-cash paid-in-kind interest expense		-			201		-			201
Gain from change in fair value of debt		-			-		(648	)		(648	)
Balance - December 31, 2014	$	-		$	26,108	$	(648	)	$	25,460

Changes in certain inputs into the lattice model can have a significant impact on changes in the estimated fair value of the 2017 Notes. For example, the estimated fair value will generally decrease with: (i) a decline in the stock price; (ii) decreases in the estimated stock volatility; and (iii) a decrease in the estimated credit spread. The change in the estimated fair value of the 2017 Notes during the year ended December 31, 2014, represents an unrealized gain which has been recorded as a gain from change in fair value of 2017 Notes in the consolidated statements of operations.

Secured Debt.

The following table sets forth information pertaining to the Company’s secured debt issued to TriplePoint Capital LLC (“TriplePoint”) which is included in the Company’s consolidated balance sheets (in thousands).

	December 31,
	2014			2013
Secured debt
TriplePoint - September 2010 Advance	$	-		$	917
TriplePoint - October 2011 Advance		-			6,657
TriplePoint - January 2012 Advance		-			3,495
TriplePoint - Matures May 2017		822			-
Total secured debt		822			11,069
Less:
Unamortized debt discounts		(49	)		(942	)
		773			10,127
Less current portion of debt		(288	)		(788	)
Long-term portion of debt	$	485		$	9,339

Debt discounts associated with the issuance of the Company’s secured debt and convertible notes are recorded on the consolidated balance sheets as a reduction to related debt balances. The Company amortizes debt discount to interest expense over the term of the debt or expected life of the debt using the effective interest method.

Gevo Loan Agreement. In August 2010, Gevo, Inc. entered into a loan and security agreement (the “Gevo Loan Agreement”) with TriplePoint, pursuant to which the Company borrowed $5.0 million. In July 2012, the Company used $5.4 million of the proceeds from the July 2012 offering of the 2022 Notes to pay in full all amounts outstanding under the Gevo Loan Agreement, including an end-of-term payment equal to 8% of the amount borrowed.

Original Agri-Energy Loan Agreement. In August 2010, Gevo Development borrowed $12.5 million from TriplePoint to finance its acquisition of Agri-Energy. In September 2010, upon completion of the acquisition, the loan and security agreement (the “Original Agri-Energy Loan Agreement”) was amended to make Agri-Energy the borrower under the facility. In December 2013, the Company used $5.1 million of the proceeds from the offering of common stock units that was completed in December 2013 to pay off the remaining $5.1 million in outstanding principal under this loan. Pursuant to the amendments described below, the Company had also agreed to pay the end-of-term payment of $1.0 million associated with this loan in 12 equal monthly payments commencing January 2014 and ending December 2014.

Amended Agri-Energy Loan Agreement. In October 2011, the Original Agri-Energy Loan Agreement was amended and restated (the “Amended Agri-Energy Loan Agreement”) to provide Agri-Energy with additional term loan facilities of up to $15.0 million to pay a portion of the costs, expenses, and other amounts associated with the retrofit of the Agri-Energy Facility to produce isobutanol. The Amended Agri-Energy Loan Agreement includes customary affirmative and negative covenants for agreements of this type and events of default. In October 2011, Agri-Energy borrowed $10.0 million under the additional term loan facilities which matures in October 2015. In January 2012, Agri-Energy borrowed an additional $5.0 million under the additional term loan facilities which matures December 2015, bringing the total borrowed under the additional term loan facilities to $15.0 million. The aggregate amount outstanding under the additional term loan facilities bears interest at a rate equal to 11% and is subject to an end-of-term payment equal to 5.75% of the amount borrowed. As security for its obligations under the Amended Agri-Energy Loan Agreement, Agri-Energy granted TriplePoint a security interest in and lien upon all of its assets. Gevo, Inc. also guaranteed Agri-Energy’s obligations under the Amended Agri-Energy Loan Agreement. As additional security, concurrently with the execution of the Amended Agri-Energy Loan Agreement, (i) Gevo Development entered into a limited recourse continuing guaranty in favor of TriplePoint, (ii) Gevo Development entered into an amended and restated limited recourse membership interest pledge agreement in favor of TriplePoint, pursuant to which it pledged the membership interests of Agri-Energy as collateral to secure the obligations under its guaranty and (iii) Gevo, Inc. entered into an amendment to its security agreement with TriplePoint (the “Gevo Security Agreement”), which secured its guarantee of Agri-Energy’s obligations under the Amended Agri-Energy Loan Agreement.

June 2012 Amendments. In June 2012, Gevo, Inc. entered into (i) an amendment (the “Security Agreement Amendment”) to the Gevo Security Agreement and (ii) an amendment (the “Gevo Loan Amendment”) to the Gevo Loan Agreement. In addition, concurrently with the execution of the Security Agreement Amendment and the Gevo Loan Amendment, Agri-Energy entered into an amendment to the Amended Agri-Energy Loan Agreement. These amendments, among other things, permitted the issuance of the 2022 Notes.

December 2013 Amendments. In December 2013, Gevo, Inc. entered into additional amendments to certain of its existing agreements with TriplePoint and entered into a new intellectual property assignment agreement in favor of TriplePoint to, among other things:

·	permit the issuance of warrants associated with the Company’s December 2013 offering of common stock units;

·	waive any prepayment premium (but not any end-of-term payment) with respect to the Original Agri-Energy Loan Agreement and the Amended Agri-Energy Loan Agreement;

·	expand the events of default to add as an event of default the repurchase of the Warrants;

·	grant TriplePoint a lien and security interest in all of the intellectual property of the Company;

·	re-price the three outstanding warrants to purchase common stock of the Company that are held by TriplePoint, which as of December 31, 2014 are exercisable in the aggregate for 388,411 shares of the Company’s common stock, to reflect an exercise price equal to $1.18 per share;

·	waive the requirement for Agri-Energy to make principal amortization payments on the Amended Agri-Energy Loan Agreement through December 31, 2014 (the “Restructure Period”);

raise the interest rates under the Amended Agri-Energy Loan Agreement to 13% during the Restructure Period (provided that such rate will return to 11% following the Restructure Period so long as no event of default under the Amended Agri-Energy Loan Agreement shall be continuing on the last day of the Restructure Period); and

during the period beginning January 2015, and continuing through and including the final monthly installment due under the Amended Agri-Energy Loan Agreement, adjust the monthly payment due and payable to 50% of the fully amortizing amount of principal and interest otherwise due and payable for such month, applied first to outstanding accrued interest and then to principal, with the remaining 50% portion of such required payments of principal and interest for such month accruing and made due and payable at the time of the final monthly installment.

May 2014 Amendments. In May 2014, the Company and its subsidiaries entered into a Consent Under and Third Amendment to Amended and Restated Plain English Growth Capital Loan and Security Agreement and Omnibus Amendment to Loan Documents (the “2014 Amendment”) pursuant to which TriplePoint amended its agreements with the Company and its subsidiaries and consented to (a) the execution, delivery, and performance of the Loan Agreement, the Exchange and Purchase Agreement, the Registration Rights Agreement, the 2017 Notes Indenture, the 2017 Notes, and the other documents related thereto (collectively the “Senior Loan Documents”); (b) the incurrence of the Term Loan with Whitebox and any other indebtedness under the Senior Loan Documents (collectively, the “Senior Indebtedness”); (c) the consummation of the exchange of the Term Loan for the 2017 Notes; (d) the offering, issuance and sale of the 2017 Notes to Whitebox and the conversion of any 2017 Notes into the common stock of the Company pursuant to the terms of the 2017 Notes Indenture; (e) the guaranty of the Senior Indebtedness provided by the Guarantors; (f) the liens granted by each of the Company and the Guarantors to secure the Senior Indebtedness and the other obligations under the Senior Loan Documents; (g) the consummation of any transactions contemplated by, and the terms of, the Senior Loan Documents by the Company and the Guarantors; and (h) the payment and performance of any of the obligations under the Senior Loan Documents by the Company and the Guarantors, including the making of dividends and distributions by the Guarantors to the Company for the purpose of enabling the Company to make any payments under the Senior Loan Documents.

As part of the 2014 Amendment, the Company repaid $9.8 million in principal payments due under the foregoing loan agreements with TriplePoint and entered into an amended loan agreement with TriplePoint. At such time, debt issuance costs were written off. At December 31, 2014, the amended loan agreement had a principal balance of $0.8 million, which amortizes over 36 months and bears interest at a rate equal to 9% per annum and matures in May 2017. There were no additional concessions or terms of the agreement which would require recognition of a gain or loss due to this amended agreement. As of December 31, 2014, Agri-Energy has granted TriplePoint a junior security interest in all of its assets as security for its obligations under the Amended Agri-Energy Loan Agreement.

On July 31, 2014, the Company entered into amendments to the Amended Agri-Energy Loan Agreement and the Gevo Security Agreement to, among other things, permit the offering and issuance of the 2014 Warrants and the incurrence of indebtedness by the Company under such warrants.

On January 28, 2015, the Company entered into further amendments to the Amended Agri-Energy Loan Agreement and the Gevo Security Agreement to, among other things, permit the offering and issuance of additional warrants and the incurrence of indebtedness by the Company under such additional warrants.

2022 Notes

The following table sets forth information pertaining to the 2022 Notes which is included in the Company’s consolidated balance sheets (in thousands).

	Embedded Derivatives			Principal Amount of 2022 Notes			Debt Discount			Total
Balance - December 31, 2012	$	11,000		$	45,000		$	(30,446	)	$	25,554
Amortization of debt discount		-			-			3,300			3,300
Write-off of debt discount associated with conversion of debt		-			-			11,277			11,277
Gain from change in fair value of embedded derivatives		(3,114	)		-			-			(3,114	)
Conversion		(4,416	)		(18,100	)		-			(22,516	)
Balance - December 31, 2013	$	3,470		$	26,900		$	(15,869	)	$	14,501
Amortization of debt discount		-			-			2,648			2,648
Gain from change in fair value of embedded derivatives		(3,470	)		-			-			(3,470	)
Balance - December 31, 2014	$	-		$	26,900		$	(13,221	)	$	13,679

In July 2012, the Company sold $45.0 million in aggregate principal amount of 2022 Notes, with net proceeds of $40.9 million, after accounting for $2.7 million and $1.4 million of discounts and issue costs, respectively. The 2022 Notes bear interest at 7.5% which is to be paid semi-annually in arrears on January 1 and July 1 of each year.The 2022 Notes will mature in July 2022, unless earlier repurchased, redeemed or converted. During the years ended December 31, 2014, 2013 and 2012, the Company recorded $2.8 million, $3.4 million and $0.4 million, respectively, of non-cash interest expense related to the amortization of debt discounts and issue costs and recorded $2.0 million, $2.3 million and $1.6 million, respectively, of cash interest expense related to the 2022 Notes. The amortization of debt issue costs and debt discounts and cash interest are included as a component of interest expense in the consolidated statements of operations. The Company amortizes debt discounts and debt issue costs associated with the 2022 Notes using an effective interest rate of 40% from the issuance date through July 2017, a five-year period, which represents the date the holders can require the Company to repurchase the 2022 Notes.

The 2022 Notes are convertible at an initial conversion rate of 175.6697 shares of the Company’s common stock per $1,000 principal amount of 2022 Notes, subject to adjustment in certain circumstances as described in the Indenture. This is equivalent to an initial conversion price of approximately $5.69 per share of common stock. Holders may convert the 2022 Notes at any time prior to the close of business on the third business day immediately preceding the maturity date of July 1, 2022.

If a holder elects to convert its 2022 Notes prior to July 1, 2017, such holder shall be entitled to receive, in addition to the consideration upon conversion, a Coupon Make-Whole Payment. The Coupon Make-Whole Payment is equal to the sum of the present values of the number of semi-annual interest payments that would have been payable on the 2022 Notes that a holder has elected to convert from the last day through which interest was paid up to but excluding July 1, 2017, computed using a discount rate of 2%. The Company may pay any Coupon Make-Whole Payment either in cash or in shares of common stock at its election. Under the Amended Agri-Energy Loan Agreement with TriplePoint, the Company is prohibited from making any Coupon Make-Whole Payments in cash prior to the payment in full of all remaining outstanding obligations under the Amended Agri-Energy Loan Agreement. If the Company elects to pay in common stock, the stock will be valued at 90% of the average of the daily volume weighted average prices of the Company’s common stock for the 10 trading days preceding the date of conversion. As of December 31, 2014, certain holders of the 2022 Notes elected to convert notes totaling $18.1 million, reducing the principal balance of the 2022 Notes to $26.9 million. Upon conversion, the 2022 Note holders received 3,179,608 shares of common stock in payment of converted principal of $18.1 million and, pursuant to the terms of the Indenture, such holders also received 2,957,775 shares of common stock in settlement of Coupon Make-Whole Payments of $4.9 million.

If a Make-Whole Fundamental Change (as defined in the Indenture) occurs and a holder elects to convert its 2022 Notes prior to July 1, 2017, the applicable conversion rate will increase based upon reference to the table set forth in Schedule A of the Indenture. In no event will the conversion rate increase to more than 202.0202 per $1,000 principal amount of 2022 Notes.

If a Fundamental Change (as defined in the Indenture) occurs at any time, then each holder will have the right to require the Company to repurchase all of such holder’s 2022 Notes, or any portion thereof that is an integral multiple of $1,000 principal amount, for cash at a repurchase price of 100% of the principal amount of such 2022 Notes plus any accrued and unpaid interest thereon through, but excluding, the repurchase date. Additionally, on July 1, 2017, each holder will have the right to require the Company to repurchase all of such holder’s 2022 Notes, or any portion thereof that is an integral multiple of $1,000 principal amount, for cash at a repurchase price of 100% of the principal amount of such 2022 Notes plus any accrued and unpaid interest thereon through, but excluding, the repurchase date. A Fundamental Change includes, amongst other things, the Company’s common stock ceasing to be listed on a national securities exchange. See Note 20 for information on the Company’s listing status

The Company shall have a provisional redemption right (“Provisional Redemption”) to redeem, at its option, all or any part of the 2022 Notes at a price payable in cash, beginning on July 1, 2015 and prior to July 1, 2017, provided that the Company’s common stock for 20 or more trading days in a period of 30 consecutive trading days ending on the trading day immediately prior to the date of the redemption notice exceeds 150% of the conversion price in effect on such trading day. On or after July 1, 2017, the Company shall have an optional redemption right (“Optional Redemption”) to redeem, at its option, all or any part of the 2022 Notes at a price payable in cash. The price payable in cash for the Optional Redemption or Provisional Redemption is equal to 100% of the principal amount of 2022 Notes redeemed plus any accrued and unpaid interest thereon through, but excluding, the repurchase date.

If there is an Event of Default (as defined in the Indenture) under the 2022 Notes, the holders of not less than 25% in principal amount of Outstanding Notes (as defined in the Indenture) by notice to the Company and the trustee may, and the trustee at the request of such holders shall, declare the principal amount of all the Outstanding Notes and accrued and unpaid interest thereon to be due and payable immediately.

Outstanding Obligations

The following sets forth the Company’s obligations to repay principal by year relating to its secured debt with TriplePoint and the Convertible Notes at December 31, 2014 (in thousands).

	Amount
2015	$	319
2016		348
2017		26,263
2018		-
2019 and thereafter		26,900

Total	$	53,830

Capital Stock

12 Months Ended

Dec. 31, 2014

Stockholders Equity Note [Abstract]

Capital Stock

9. Capital Stock

As of December 31, 2014, the Company has authorized 250.0 million and 10.0 million shares of common and preferred stock, respectively. The holders of the Company’s common stock have one vote per share. The board of directors has the authority, without action by its stockholders, to designate and issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. The Company’s amended and restated certificate of incorporation provides that the Company’s board of directors will be divided into three classes, with staggered three-year terms and provides that all stockholder actions must be effected at a duly called meeting of the stockholders and not by a written consent. The amended and restated certificate of incorporation also provides that only the board of directors may call a special meeting of the stockholders and requires the approval of either a majority of the directors then in office or 66 2/3% of the voting power of all then outstanding capital stock for the adoption, amendment or repeal of any provision of the Company’s amended and restated bylaws. In addition, the amendment or repeal of certain provisions of the Company’s amended and restated certificate of incorporation requires the approval of 66 2/3% of the voting power of all then outstanding capital stock.

Common Stock Offerings. In August 2014, the Company issued and sold 30,000,000 common stock units at an offering price of $0.60 per common stock unit. Each common stock unit consisted of one share of the Company’s common stock and a 2014 Warrant to purchase 0.5 shares of the Company’s common stock, resulting in net proceeds of approximately $16.4 million after deducting paid and unpaid underwriting discounts and commissions and other offering costs. The Company allocated $2.4 million of the proceeds from the offering of common stock units to the 2014 Warrants based upon their estimated value which was recorded as additional paid-in capital.

In December 2013, the Company issued and sold 21,303,750 common stock units at an offering price of $1.35 per common stock unit. Each common stock unit consisted of one share of the Company’s common stock and a 2013 Warrant to purchase one share of the Company’s common stock, resulting in net proceeds of $26.4 million after deducting paid and unpaid underwriting discounts and commissions and other offering costs. The Company allocated $4.0 million of the proceeds from the offering of common stock units to the 2013 Warrants based upon their estimated value which was recorded as additional paid-in capital.

In July 2012, the Company issued 12.5 million shares of its common stock at an offering price of $4.95 per share, resulting in net proceeds of $57.4 million, after deducting underwriting discounts and commissions and other offering costs.

In February 2011, the Company completed its initial public offering issuing 8,222,500 shares of common stock at an offering price of $15.00 per share, resulting in net proceeds of $110.4 million, after deducting underwriting discounts and commissions and other offering costs. Upon the closing of the initial public offering, the Company’s outstanding shares of convertible preferred stock were automatically converted into 16,329,703 shares of common stock and the outstanding convertible preferred stock warrants were automatically converted into common stock warrants to purchase a total of 398,032 shares of common stock.

Common Stock Warrants.

The following table sets forth a summary of outstanding warrants to purchase shares of the Company’s common stock as of December 31, 2014.

	Issue Date	Expiration Date	Outstanding		Exercise Price
Common Stock Warrants	December 2013	December 2018		21,303,550	$	1.43
Common Stock Warrants	August 2014	August 2019		15,000,000	$	0.85
CDP Gevo, LLC	September 2009	September 2016		812,771	$	2.70
TriplePoint Capital LLC	August 2010	August 2017		199,999	$	1.18
TriplePoint Capital LLC	October 2011	October 2018		157,035	$	1.18
TriplePoint Capital LLC	January 2012	October 2018		31,407	$	1.18
Genesis Select	June 2013	June 2018		30,000	$	1.63
Virgin Green Fund I, L.P.	January 2008	February 2016		28,786	$	5.48
Total				37,563,548

See Note 13 for a discussion of the warrants issued to CDP Gevo, LLC (“CDP”) for the purchase of shares of the Company’s common stock. See Note 7 for a discussion of all Warrants issued and subsequent changes in the exercise price.

In connection with signing its loan agreements with TriplePoint, the Company has issued warrants to purchase shares of its common stock. The fair values of the warrants were estimated using the Black-Scholes option pricing model. The Company records the fair value of these warrants as debt discount which is amortized to interest expense over the terms of the borrowing. In conjunction with the December 2013 amendment to the debt agreements with TriplePoint (see Note 8), the exercise price for the three outstanding warrants to purchase shares of the Company’s common stock held by TriplePoint were re-priced to reflect an exercise price equal $1.18. The Company calculated the estimated incremental fair value of the warrants based upon the Black-Scholes option pricing model. The incremental fair value is determined as the difference between the estimated fair value of the warrants immediately prior the re-pricing and the estimated fair value of the warrants after the re-pricing. The Company recorded the incremental fair value, $0.2 million, as a component of debt discount.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Equity Incentive Plans	12 Months Ended
Equity Incentive Plans	Dec. 31, 2014
Equity [Abstract]
Equity Incentive Plans	10. Equity Incentive Plans 2006 Omnibus Securities and Incentive Plan. During 2006, the Company established the Gevo, Inc. 2006 Omnibus Securities and Incentive Plan (the “2006 Plan”). Pursuant to the 2006 Plan, the Company granted stock awards to employees, directors, and consultants of the Company. Upon adoption of the Gevo, Inc. 2010 Stock Incentive Plan (as amended, the “2010 Plan”), no further grants can be made under the 2006 Plan. At December 31, 2014, a total of 1,612,589 shares of Gevo common stock were reserved for issuance upon the exercise of outstanding stock option awards under the 2006 Plan. To the extent outstanding awards under the 2006 Plan expire, or are forfeited, cancelled, settled, or become unexercisable without the issuance of shares, the shares of common stock subject to such awards will be available for future issuance under the 2010 Plan. 2010 Stock Incentive Plan. In February 2011, the Company’s stockholders approved the 2010 Plan, which was subsequently amended in June 2013, and provides for the grant of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, restricted stock units and other equity awards to employees of the Company. Stock options granted under the 2010 Plan have an exercise price that is at least equal to the fair market value of the Company’s common stock on the date the stock option is granted and expire ten years after the date of grant. At December 31, 2014, a total of 1,957,844 shares of Gevo common stock were reserved for issuance upon the exercise of outstanding stock option awards under the 2010 Plan, and an additional 1,481,824 shares were available for grant. Employee Stock Purchase Plan. In February 2011, the Company’s stockholders approved the ESPP. The offering periods for the ESPP are from January 1 to June 30 and from July 1 to December 31 of each calendar year. The Company has reserved 1,285,643 shares of common stock for issuance under the ESPP, of which 1,150,939 shares as of December 31, 2014 are available for future issuance. The purchase price of the common stock under the ESPP is 85% of the lower of the fair market value of a share of common stock on the first or last day of the purchase period.

Stock-Based Compensation

12 Months Ended

Dec. 31, 2014

Share Based Compensation [Abstract]

Stock-Based Compensation

11. Stock-Based Compensation

Stock-Based Compensation Expense. The following table sets forth the Company’s stock-based compensation expense (in thousands).

	Year Ended December 31,
	2014		2013		2012
Stock options and ESPP awards
Research and development	$	303	$	640	$	808
Selling, general and administrative		837		1,837		2,628

Restricted stock awards
Research and development		487		14		328
Selling, general and administrative		1,233		1,381		1,599

Warrants issued
Selling, general and administrative		-		39		2,616
Non-cash stock-based compensation		2,860		3,911		7,979

Modified stock option awards
Selling, general and administrative		-		-		890

Purchase of Class B interests of Gevo Development from CDP for cash
Selling, general and administrative		-		-		74
Cash stock-based compensation		-		-		964

Total stock-based compensation	$	2,860	$	3,911	$	8,943

Determining Fair Value of Share-Based Payment Awards. The following table sets forth the Black-Scholes option pricing model assumptions and resulting grant date fair value for stock options granted.

	Year Ended December 31,
	2014			2013			2012

Risk-free interest rate		1.74	%		1.26	%		1.17	%
Expected dividend yield	None			None			None
Expected volatility factor		71.13	%		71.96	%		78.86	%
Expected option life (in years)		5.75		5.8			5.78
Weighted average grant date fair value	$	0.89		$	1.18		$	4.74

Due to the Company’s limited history of grant activity, the expected life of options granted was estimated using the “simplified method” in accordance with SEC Staff Accounting Bulletin 110, where the expected life equals the arithmetic average of the vesting term and the original contractual term of the options. The volatility factor was determined based upon management’s estimate using inputs from comparable public companies. The risk-free interest rate assumption is determined based upon observed interest rates appropriate for the expected term of the Company’s employee stock options. The dividend yield assumption is based on the Company’s history of dividend payouts.

An annual forfeiture rate is estimated at the time of grant for all share-based payment awards, and revised, if necessary, in subsequent periods if the actual forfeiture rate differs from the Company’s estimate. Forfeitures have been estimated by the Company based upon historical and expected forfeiture experience. Estimated forfeiture rates used for the periods presented were from 0% to 5%.

Stock Option Award Activity. Stock option activity under the Company’s option plans at December 31, 2013 and changes during the year ended December 31, 2014 were as follows.

						Weighted-
						Average
				Weighted-		Remaining
				Average		Contractual
	Number of			Exercise		Term		Aggregate
	Options			Price		(years)		Intrinsic Value
Options outstanding at December 31, 2013		2,871,563		$	5.15	6.57		$	478
Granted		1,128,536			1.40
Canceled or forfeited		(470,686	)		6.90
Exercised		(5,000	)		0.47
Options outstanding at December 31, 2014		3,524,413		$	3.72	5.61		$	-

Options exercisable at December 31, 2014		2,532,633		$	4.54		5.16	$	-

Options vested and expected to vest at December 31, 2014		3,519,749		$	3.72		5.61	$	-

The aggregate intrinsic values in the table above represent the total pre-tax intrinsic values (the difference between the closing price of Gevo’s common stock on the last trading day of the 2014 calendar year and the exercise price, multiplied by the number of in-the-money stock option shares) that would have been received by the option holders had all in-the-money outstanding stock options been exercised on December 31, 2014. The total intrinsic value of options exercised during the years ended December 31, 2014, 2013 and 2012 was $0.0 million, $0.2 million and $2.2 million, respectively.

The following table summarizes information associated with outstanding and exercisable stock options at December 31, 2014.

	Options Outstanding						Options Exercisable
					Weighted-						Weighted-
					Average				Weighted-		Average
Range of			Weighted-		Remaining				Average		Remaining
Exercise	Number of		Average Exercise		Contractual Life		Number of		Exercise		Contractual Life
Prices	Options		Price		in Years		Options		Price		in Years
$0.46 to $0.49		377,533	$	0.46		2.35		377,533	$	0.46		2.35
$0.50 to $0.99		76,030	$	0.88		9.48		12,700	$	0.88		9.46
$1.00 to $1.89		1,847,752	$	1.48		7.52		948,553	$	1.43		6.13
$2.70 to $8.73		582,590	$	2.88		5.00		567,502	$	2.87		4.94
$9.41 to $9.57		210,466	$	9.41		6.55		196,303	$	9.41		6.51
$9.57 to $12.67		354,906	$	10.40		4.73		354,906	$	10.40		4.73
$14.81 to $19.14		224,262	$	17.17		5.58		224,262	$	17.27		5.58

As of December 31, 2014, $1.2 million of total unrecognized compensation cost related to stock options is expected to be recognized as an expense by the Company in the future over a weighted-average period of approximately two years.

The Company settles stock option exercises with newly issued common shares. No tax benefits were realized by the Company in connection with these exercises as the Company maintains net operating loss carryforwards and has established a valuation allowance against the entire tax benefit.

Restricted Stock. The Company periodically grants restricted stock awards to employees (including board members) and non-employee consultants. The vesting period for restricted stock awards granted may be based upon a service period or based upon the attainment of performance objectives. The Company recognizes stock-based compensation over the vesting period, generally three to six years, for awards that vest based upon a service period. For performance based restricted stock awards, the Company recognizes expense over the requisite service period.

Non-vested restricted stock awards at December 31, 2013 and changes during the year ended December 31, 2014 were as follows.

				Weighted-
				Average
	Number of			Grant-Date
	Shares			Fair Value
Non-vested at December 31, 2013		791,389		$	2.52
Granted		1,138,081			0.69
Vested		(983,530	)		1.54
Canceled or forfeited		(70,675	)		1.83
Non-vested at December 31, 2014		875,265		$	1.30

The total fair value of restricted stock that vested during the year ended December 31, 2014, 2013 and 2012 was $1.5 million, $1.5 million and $0.9 million, respectively. As of December 31, 2014, the total unrecognized compensation expense, net of estimated forfeitures, relating to restricted stock awards was $1.4 million, which is expected to be recognized over a weighted-average period of approximately two years.

Significant Agreements	12 Months Ended
Significant Agreements	Dec. 31, 2014
Leases [Abstract]
Significant Agreements	12. Significant Agreements Off-Take, Distribution and Marketing Agreements Exclusive Supply Agreement with LANXESS. In January 2011, the Company entered into an exclusive supply agreement, as amended, with LANXESS Inc. (“LANXESS”) pursuant to which LANXESS has granted the Company an exclusive first right to supply LANXESS and its affiliates with certain of their requirements for biobased isobutanol during the term of the agreement. The Company’s exclusive first right to supply biobased isobutanol to LANXESS and its affiliates will be subject to the terms of a supply agreement to be mutually agreed upon by the parties at a later date. Additionally, pursuant to the terms of the exclusive supply agreement the Company has granted LANXESS, subject to certain exceptions and conditions, (i) an exclusive first right to acquire its biobased isobutanol to produce isobutylene and butenes for use and sale in the field of chemicals, and (ii) an exclusive right to use the Company’s isobutanol to produce butadiene and isobutylene for use in the production of polybutadiene and butyl rubber. No amounts have been incurred under this agreement as of December 31, 2014. Off-Take and Marketing Alliance Agreement and Renewable Fuels Supply Chain Agreement with Mansfield Oil Company. In August 2011, the Company entered into a commercial off-take agreement with Mansfield Oil Company (“Mansfield”), to distribute isobutanol-based fuel into the petroleum market. The agreement allows Mansfield to blend the Company’s isobutanol for its own use, and to be a distributor of the Company’s isobutanol for a term of five years. The Company also entered into a three-year supply services agreement, with automatic one-year renewals thereafter, with C&N, a Mansfield subsidiary (“C&N”), which will provide supply chain services including logistics management, customer service support, invoicing and billing services. No amounts have been recorded under these agreements as of December 31, 2014. Ethanol Marketing Agreement with C&N, a subsidiary of Mansfield Oil Company. Substantially all ethanol sold by Agri-Energy from the date of acquisition through December 31, 2012 and during the year ended December 31, 2014 was sold to C&N pursuant to an ethanol purchase and marketing agreement. The Company did not sell any ethanol during the year ended December 31, 2013. The ethanol purchase and marketing agreement with C&N was entered into in April 2009 and automatically renews for subsequent one-year terms unless either party terminates the agreement 60 days before the end of term. Under the terms of the agreement, C&N will market substantially all of Agri-Energy’s ethanol production from the Agri-Energy Facility and will pay to Agri-Energy the gross sales price paid by the end customer less expenses and a marketing fee. Jet Fuel Supply Agreements with the Defense Logistics Agency (U.S. Air Force, U.S. Army and U.S. Navy). During September 2011, the Company was awarded a contract for the procurement of up to 11,000 gallons of alcohol-to-jet (ATJ) fuel for the purposes of certification and testing by the U.S. Air Force. The term of the agreement was through December 2012. The Company recorded $0.6 million of revenue under this award during the year ended December 31, 2012. In September 2012, the Company was awarded an additional contract by the U.S. Air Force for the procurement of up to 45,000 gallons of biojet fuel. In March 2013, the Company entered into a contract with the Defense Logistics Agency to supply the U.S. Army with 3,650 gallons of biojet fuel and in May 2013 this initial order was increased by 12,500 gallons. In September 2013, the Company entered into a contract with the Defense Logistics Agency to supply the U.S. Navy with 20,000 gallons of biojet fuel. During the years ended December 31, 2014, 2013 and 2012, the Company recorded $2.0 million, $1.9 million and $0.6 million, respectively, of revenue associated with shipments of biojet fuel under these contracts. Development and Commercialization Agreements Development and Commercialization Agreements with ICM. In October 2008, the Company signed development and commercialization agreements with ICM, Inc. (“ICM”). Under the terms of the development agreement, the Company performed commercial-scale isobutanol production trials in ICM’s research plant and facility in St. Joseph, Missouri (the “Demonstration Plant”). The Company was required to pay for or reimburse ICM for engineering fees, equipment, plant modification costs, project fees and various operating expenses. In December 2011, the development agreement was amended to extend the term indefinitely. The development agreement, as amended, may be cancelled by either party with 30 days’ prior written notice. The Company did not incur any operating expenses or capital expenditures relating to the Demonstration Plant during the years ended December 31, 2014, 2013 or 2012. The commercialization agreement, which was amended and restated in August 2011, is effective through October 2018, and outlines the terms and fees under which ICM acts as the Company’s exclusive provider of certain engineering and construction services. Also, under the commercialization agreement, the Company is ICM’s exclusive technology partner for the production of butanols, pentanols and propanols from the fermentation of sugars. The Company has also engaged ICM to perform engineering studies, plant evaluations and other services. In August 2011, the Company entered into a work agreement with ICM whereby ICM will provide engineering, procurement and construction services for the retrofit of ethanol plants. Joint Research, Development, License and Commercialization Agreement with The Coca-Cola Company. During November 2011, the Company entered into a joint research, development, license and commercialization agreement with The Coca-Cola Company (“Coca-Cola”). During the first two years of the agreement, Coca-Cola agreed to pay the Company a fixed price fee for a research program outlined in the agreement. The Company recognizes these fees as revenue over the performance period. The payments received are not refundable. The Company did not recognize revenue under this agreement during the year ended December 31, 2014 and the Company recognized $1.4 million and $1.2 million, respectively, during the years ended December 31, 2013 and 2012. License Agreement License Agreement with Cargill, Incorporated. During February 2009, the Company entered into a license agreement with Cargill, Incorporated (“Cargill”) to obtain certain biological materials and license patent rights to use a biocatalyst owned by Cargill. Under the license agreement, Cargill has granted the Company an exclusive, royalty-bearing license, with limited rights to sublicense, to use the patent rights in a certain field, as defined in the license agreement. The license agreement contains five milestone payments totaling approximately $4.3 million that are payable by the Company after each milestone is completed. During 2009, two milestones were completed and the Company recorded the related milestone amounts, along with an up-front signing fee, totaling $0.9 million, to research and development expense. During March 2010, the Company completed milestone number three and recorded the related milestone amount of $2.0 million to research and development expense at its then-current present value of $1.6 million because the milestone payment was paid over a period greater than 12 months from the date that it was incurred. At December 2012, the Company had not completed milestone number four. However, under the terms of the agreement, the Company was entitled to pay a $0.5 million license fee in lieu of completing milestone number four. This fee was paid in March 2013 through the issuance of 250,000 shares of the Company’s common stock to Cargill. Milestone number five included in the license agreement representing potential payments of up to $1.0 million, which is due by December 2015, has not been met as of December 31, 2014 and no amount has been recorded as a liability for this milestone. Upon commercialization of a product which uses Cargill’s biological material or is otherwise covered by the patent rights under the license agreement, a royalty based on net sales is payable by the Company, subject to a minimum royalty amount per year, as defined in the license agreement, and up to a maximum amount per year. The license agreement provides an option for Cargill to purchase a nonexclusive, royalty-bearing license for the use of a Company biocatalyst that utilizes the Cargill biological material or licensed patents for a royalty rate equal to the lowest rate offered to any third party. The Company may terminate the license agreement at any time upon 90 days’ prior written notice. Unless terminated earlier, the license agreement remains in effect until the later of December 31, 2025 and the date that no licensed patent rights remain. Other Significant Agreements In June 2011, the Company announced that it had successfully produced fully renewable and recyclable polyethylene terephthalate (“PET”) in cooperation with Toray Industries, Inc. (“Toray Industries”). Working directly with Toray Industries, the Company employed prototypes of commercial operations from the petrochemical and refining industries to make para-xylene from isobutanol. Toray Industries used the Company’s bio-para-xylene (“bio-PX”) and commercially available renewable mono ethylene glycol to produce fully renewable PET films and fibers. In June 2012, the Company entered into a definitive agreement with Toray Industries, as amended in October 2013, for the joint development of an integrated supply chain for the production of bio-PET. Pursuant to the terms of the agreement with Toray Industries, the Company received $1.0 million which was used by the Company for the design and construction of a demonstration plant. In May 2014, the Company successfully shipped the requisite volumes of bio-PX associated with its contract with Toray Industries and, as a result, the Company recognized the $1.0 million, as well as revenue associated with the sale of the bio-PX, as a component of hydrocarbon revenue in the second quarter of 2014. At December 31, 2013, the Company included the $1.0 million as deferred revenue, a component of accounts payable and accrued liabilities in its consolidated balance sheets. In December 2011, the Company entered into a commercial off-take and marketing agreement with Land O’Lakes Purina Feed LLC (“Land O’Lakes Purina Feed”) for the sale of iDGs™ produced by the Agri-Energy Facility. Land O’ Lakes Purina Feed provides farmers and ranchers with an extensive line of agricultural supplies (feed, seed, and crop protection products) and services. Pursuant to the agreement, Land O’Lakes Purina Feed will be the exclusive marketer of the Company’s iDGs™ and modified wet distiller’s grains for the animal feed market. The agreement has an initial three-year term following the first commercial sales of iDGs™ with automatic one-year renewals thereafter unless terminated by one of the parties. Further, the Company’s plans to work with Land O’Lakes Purina Feed to explore opportunities to upgrade the iDGs™ for special value-added applications in feed markets. No amounts have been incurred under this agreement as of December 31, 2014. Land O’Lakes Purina Fees also provides marketing services for the sale of the Company’s ethanol distiller grains. Within its research and development activities, the Company routinely enters into research and license agreements with various entities. Future royalty payments may apply under these license agreements if the technologies are used in future commercial products. In addition, the Company may from time to time make gifts to universities and other organizations to expand research activities in its fields of interest. Any amounts paid under these agreements are generally recorded as research and development expenses as incurred. The Company has been awarded grants or cooperative agreements from a number of government agencies, including the U.S. Department of Energy, U.S. National Science Foundation, U.S. Environmental Protection Agency, U.S. Army Research Labs and the U.S. Department of Agriculture. Any recorded revenues related to these grants and cooperative agreements are recorded within grant and other revenue in the Company’s consolidated statements of operations.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

Gevo Development

12 Months Ended

Dec. 31, 2014

Equity [Abstract]

Gevo Development

13. Gevo Development

Gevo, Inc. currently owns 100% of the outstanding equity interests of Gevo Development. Gevo Development has two classes of membership interests outstanding. Gevo, Inc. is the sole owner of the class A interests. Prior to September 2010, CDP, was the sole owner of the class B interests, which comprise 10% of the outstanding equity interests of Gevo Development. In September 2010, Gevo, Inc. became the sole owner of Gevo Development by acquiring 100% of the class B interests in Gevo Development from CDP pursuant to an equity purchase agreement. In exchange for the class B interests, CDP received aggregate consideration of $1.1 million.

The original issuance of the class B interests was considered to be a grant of non-employee stock-based compensation. As vesting of the awards was dependent on counterparty performance conditions (the acquisition and retrofit of a biorefinery plant), no compensation expense had been recorded prior to September 2010 because the lowest aggregate fair value of the awards was zero. Upon the purchase of the class B interests in September 2010, the Company recorded stock-based compensation of $0.8 million, which reflected the amount paid during 2010 for the class B interests that were not dependent on counterparty performance. The Company recorded stock compensation of $0.1 million during the year ended December 31, 2012.

Gevo, Inc. made capital contributions to Gevo Development of $26.5 million, $29.6 million and $55.5 million, respectively, during the years ended December 31, 2014, 2013 and 2012.

The following table sets forth (in thousands) the net loss incurred by Gevo Development (including Agri-Energy after it was acquired in September 2010) which has been fully allocated to Gevo, Inc.’s capital contribution account based upon its capital contributions (for the period prior to September 2010) and 100% ownership (for the period after September 2010).

	Year Ended December 31,
	2014			2013			2012
Gevo Development Net Loss	$	(14,778	)	$	(19,243	)	$	(15,870	)

In connection with the formation of Gevo Development in September 2009, the Company granted CDP a warrant to purchase 858,000 shares of the Company’s common stock. The warrant has an exercise price of $2.70 per share which represented the estimated fair value of Gevo, Inc.’s common stock on the date of grant. The warrant expires in September 2016, unless terminated earlier as provided in the warrant agreement.

In September 2010, the beneficial owners of the equity interests of CDP became employees of Gevo, Inc. and the warrant agreement was amended and restated to provide that 50% of the warrant shares granted under such warrant agreement would vest in September 2010. The remaining warrant shares were to vest over a two-year period beginning in September 2010, subject to acceleration and termination in certain circumstances. The Company valued the warrant shares at $14.0 million. Effective March 23, 2012, the employment of the beneficial owners of CDP was terminated. Pursuant to the terms of the warrant agreement, all unvested warrant shares became immediately vested and, as such, the Company recorded $2.6 million of stock-based compensation expense during the year ended December 31, 2012.

Since its formation, Gevo Development has been and continues to be considered a variable interest entity. Gevo, Inc., the primary beneficiary of Gevo Development, has both (i) the power to direct the activities of Gevo Development that most significantly impact Gevo Development’s economic performance and (ii) the obligation to absorb losses of Gevo Development that could potentially be significant to Gevo Development or the right to receive benefits from Gevo Development that could potentially be significant to Gevo Development. As such, Gevo Development is consolidated. The accounts of Agri-Energy are consolidated within Gevo Development as a wholly-owned subsidiary. As of December 31, 2014 and 2013, Gevo Development does not have any assets that can be used only to settle obligations of Gevo Development. In addition, as of December 31, 2014, under the terms of the Amended Agri-Energy Loan Agreement with TriplePoint, as amended, subject to certain limited exceptions, Agri-Energy is only permitted to pay if the following conditions are satisfied: (i) the Retrofit of the Agri-Energy Facility is complete and the facility is producing commercial volumes of isobutanol, (ii) its net worth is greater than or equal to $10.0 million, and (iii) no event of default has occurred and is continuing under the agreement. No gain or loss was recognized by the Company upon the initial consolidation of Gevo Development.

Redfield Energy, LLC	12 Months Ended
Redfield Energy, LLC	Dec. 31, 2014
Equity Method Investments And Joint Ventures [Abstract]
Redfield Energy, LLC	14. Redfield Energy, LLC In June 2011, Gevo Development entered into an isobutanol joint venture agreement (the “Joint Venture Agreement”) with Redfield Energy, LLC, a South Dakota limited liability company (“Redfield”), and executed the second amended and restated operating agreement of Redfield (together with the Joint Venture Agreement, the “Joint Venture Documents”). Under the terms of the Joint Venture Documents, Gevo Development and Redfield have agreed to work together to retrofit Redfield’s approximately 50 million gallon per year ethanol production facility located near Redfield, South Dakota (the “Redfield Facility”) for the commercial production of isobutanol. Under the terms of the Joint Venture Agreement, Redfield has issued 100 Class G membership units in Redfield (the “Class G Units”) to Gevo Development. Gevo Development is the sole holder of Class G units, which entitle Gevo Development to certain information and governance rights with respect to Redfield, including the right to appoint two members of Redfield’s 11-member board of managers. The Class G units currently carry no interest in the allocation of profits, losses or other distributions of Redfield and no voting rights. Such rights will vest upon the commencement of commercial isobutanol production at the Redfield Facility, at which time Gevo Development anticipates consolidating Redfield’s operations because Gevo anticipates it will control the activities that are most significant to the entity. Gevo Development will be responsible for all costs associated with the retrofit of the Redfield Facility. Redfield will remain responsible for certain expenses incurred by the facility including certain repair and maintenance expenses and any costs necessary to ensure that the facility is in compliance with applicable environmental laws. The Company anticipates that the Redfield Facility will continue its current ethanol production activities during much of the retrofit. Once the retrofit assets have been installed, the ethanol production operations will be suspended to enable testing of the isobutanol production capabilities of the facility (the “Performance Testing Phase”). During the Performance Testing Phase, Gevo Development will be entitled to receive all revenue generated by the Redfield Facility and will make payments to Redfield to cover the costs incurred by Redfield to operate the facility plus the profits, if any, that Redfield would have received if the facility had been producing ethanol during that period (the “Facility Payments”). Gevo Development has also agreed to maintain an escrow fund during the Performance Testing Phase as security for its obligation to make the Facility Payments. If certain conditions are met, commercial production of isobutanol at the Redfield Facility will begin upon the earlier of the date upon which certain production targets have been met or the date upon which the parties mutually agree that commercial isobutanol production at the Redfield Facility will be commercially viable at the then-current production rate. At that time, (i) Gevo Development will have the right to appoint a total of four members of Redfield’s 11-member board of managers, and (ii) the voting and economic interests of the Class G units will vest and Gevo Development, as the sole holder of the Class G Units, will be entitled to a percentage of Redfield’s profits, losses and distributions, to be calculated based upon the demonstrated isobutanol production capabilities of the Redfield Facility. Gevo Development, or one of its affiliates, will be the exclusive marketer of all products produced by the Redfield Facility once commercial production of isobutanol has begun. Additionally, Gevo, Inc. will license the technology necessary to produce isobutanol at the Redfield Facility to Redfield, subject to the continuation of the marketing arrangement described above. In the event that the isobutanol production technology fails or Redfield is permanently prohibited from using such technology, Gevo Development will forfeit the Class G Units and lose the value of its investment in Redfield. Gevo, Inc. entered into a guaranty effective as of June 2011, pursuant to which it has unconditionally and irrevocably guaranteed the payment by Gevo Development of any and all amounts owed by Gevo Development pursuant to the terms and conditions of the Joint Venture Agreement and certain other agreements that Gevo Development and Redfield expect to enter into in connection with the retrofit of the Redfield Facility. As of December 31, 2014, the Company has incurred $0.4 million in preliminary project engineering and permitting process costs for the future retrofit of the Redfield Facility which have been recorded on the Company’s consolidated balance sheets in deposits and other assets. Gevo has no obligation to Retrofit the Redfield Facility.

Income Taxes

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

15. Income Taxes

There is no provision for income taxes because the Company has incurred operating losses since inception. As of December 31, 2014, the Company had federal and state net operating loss carryforwards of approximately $289.9 million which may be used to offset future taxable income. The Company also had federal research and development tax credit carryforwards and other federal tax credit carryforwards which aggregate to $6.0 million at December 31, 2014. These carryforwards expire at various times through 2034 and may be limited in their annual usage by Section 382 of the Internal Revenue Code, as amended, relating to ownership changes.

The following table sets forth the tax effects of temporary differences that give rise to significant portions of the Company’s net deferred tax assets (in thousands).

	December 31,
	2014			2013
Deferred tax assets:
Net operating loss carryforwards	$	115,870		$	96,748
Research and other credits		6,047			5,502
Other temporary differences		(2,478	)		2,768
Deferred tax assets - before valuation allowance		119,439			105,018
Valuation allowance		(119,439	)		(105,018	)
Net deferred tax assets - after valuation allowance	$	-		$	-

The Company’s deferred tax assets represent an unrecognized future tax benefit. The Company recognizes uncertain tax positions net, against any operating losses or applicable research credits as they arise. Currently, there are no uncertain tax positions recognized at December 31, 2014. The Company has provided a full valuation allowance on its deferred tax assets at December 31, 2014 and 2013, as management believes it is more likely than not that the related deferred tax asset will not be realized. The reported amount of income tax expense differs from the amount that would result from applying domestic federal statutory tax rates to pretax losses, primarily because of changes in the valuation allowance.

The following table sets forth reconciling items from income tax computed at the statutory federal rate.

	Year Ended December 31,
	2014			2013			2012
Federal income tax at statutory rate		35.0	%		35.0	%		35.0	%
State income taxes, net of federal benefits		4.5	%		5.7	%		6.2	%
Research and other credits		-1.3	%		-2.2	%		0.0	%
Permanent deductions		-2.2	%		-1.5	%		-2.5	%
Valuation allowance		-36.0	%		-37.0	%		-38.7	%

Effective tax rate		0.0	%		0.0	%		0.0	%

Accounting literature regarding liabilities for unrecognized tax benefits provides guidance for the recognition and measurement in financial statements of uncertain tax positions taken or expected to be taken in a tax return. The Company has concluded that there are no significant uncertain tax positions requiring recognition in the consolidated financial statements. The Company’s evaluation was performed for the tax periods from inception to December 31, 2014, which remain subject to examination by major tax jurisdictions as of December 31, 2014.

The Company may from time to time be assessed interest or penalties by major tax jurisdictions, although there have been no such assessments historically, with any material impact to its financial results. The Company would recognize interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying Consolidated Statements of Operations. Accrued interest and penalties would be included within the related tax liability line in the Consolidated Balance Sheets.

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2014
Employee Benefit Plan [Abstract]
Employee Benefit Plan	16. Employee Benefit Plan The Company’s employees participate in the Gevo, Inc. 401(k) Plan (the “401(k) Plan”). Subject to certain eligibility requirements, the 401(k) Plan covers substantially all employees after three months of service with quarterly entry dates. Employee contributions are deposited by the Company into the 401(k) Plan and may not exceed the maximum statutory contribution amount. The Company may make matching and/or discretionary contributions to the 401(k) Plan. Effective January 2008, the Company began providing an employer match of 100% up to a maximum of 5% of compensation per employee, which vested over a period of approximately two years. Effective January 2013, the Company elected to cease providing an employer match. During the year ended December 31, 2012, the Company recorded $0.5 million in matching contributions.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2014

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

17. Commitments and Contingencies

Legal Matters. On January 14, 2011, Butamax filed a complaint (the “Complaint”) against the Company in the United States District Court for the District of Delaware (“Delaware District Court”), as Case No. 1:11-cv-00054-SLR, alleging that the Company is infringing one or more claims made in U.S. Patent No. 7,851,188 (the “’188 Patent”), entitled “Fermentive Production of Four Carbon Alcohols.” The ’188 Patent, which has been assigned to Butamax, claims certain recombinant microbial host cells that produce isobutanol and methods for the production of isobutanol using such host cells. Butamax is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. On March 25, 2011, the Company filed a response to the Complaint, denying Butamax’s allegations of infringement and raising affirmative defenses.

On August 11, 2011, Butamax amended the Complaint to include allegations that the Company is infringing one or more claims made in U.S. Patent No. 7,993,889 (the “’889 Patent”), also entitled “Fermentive Production of Four Carbon Alcohols” (the “Amended Complaint”). The ’889 Patent, which has been assigned to Butamax, claims methods for producing isobutanol using certain recombinant yeast microorganisms expressing an engineered isobutanol biosynthetic pathway. The Company believes that the Amended Complaint is without merit and will continue to aggressively defend its intellectual property rights.

On September 13, 2011, the Company filed an answer to the Amended Complaint in which it asserted counterclaims against Butamax and DuPont for infringement of U.S. Patent No. 8,017,375 (the “’375 Patent”), entitled “Yeast Organism Producing Isobutanol at a High Yield” and U.S. Patent No. 8,017,376 (the “’376 Patent”), entitled “Methods of Increasing Dihydroxy Acid Dehydratase Activity to Improve Production of Fuels, Chemicals, and Amino Acids.” The counterclaims sought a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. These counterclaims were set for trial in August 2013. On July 26, 2013, the Delaware District Court issued an order regarding claim construction and summary judgment of the Company’s counterclaims involving the ’375 and ’376 Patents. Both parties had asked the Delaware District Court to resolve certain issues regarding the ’375 and ’376 Patents without a trial by seeking summary judgment from the Delaware District Court. Butamax had filed motions seeking summary judgment that it did not infringe such patents and the Delaware District Court granted Butamax’s motions on this issue. Butamax had also moved for summary judgment of invalidity on both patents. The Delaware District Court granted Butamax’s motion of invalidity on the ’375 Patent, but denied Butamax’s motion of invalidity on the ’376 Patent. On August 8, 2013, an order was issued by the Delaware District Court which entered a final judgment of non-infringement in favor of Butamax and DuPont with respect to the claims of the ’375 and ’376 Patents. The August 8, 2013 order also entered a final judgment of invalidity in favor of Butamax and DuPont with respect to the claims of the ’375 Patent. In addition, it was further ordered that the Butamax and DuPont claims and counterclaims relating to the unenforceability of the ’375 Patent, and the invalidity and/or unenforceability of the ’376 Patent, would be dismissed without prejudice, and that the Butamax and DuPont claims for exceptional case, attorney’s fees and/or costs would be preserved for later presentation to the Delaware District Court. As a result of the August 8, 2013 order, a trial did not occur on August 12, 2013 as previously scheduled. On August 26, 2014, Butamax and DuPont’s claims for exceptional case, attorney’s fees and/or costs were denied.

On September 22, 2011, Butamax filed a motion for preliminary injunction with respect to the alleged infringement by the Company of one or more claims made in the ’889 Patent.

On January 24, 2012, the Company filed a complaint in the Delaware District Court, as Case No. 1:12-cv-00070-SLR, alleging that Butamax and DuPont are infringing one or more claims made in U.S. Patent No. 8,101,808 (the “’808 Patent”) entitled “Recovery of Higher Alcohols from Dilute Aqueous Solutions.” The ’808 Patent claims methods to produce a C3-C6 alcohol—for example, isobutanol—through fermentation and to recover that alcohol from the fermentation medium. The Company sought a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. On May 8, 2013, the Company stipulated and agreed to dismiss without prejudice the ’808 Patent suit against Butamax, DuPont, or their affiliates, with each side bearing its own costs and fees in the action. The Company further stipulated and agreed with Butamax that the Company shall not re-assert the ’808 Patent against Butamax, DuPont, or their respective affiliates until a final Certificate of Reexamination is received from the U.S. Patent and Trademark Office (“USPTO”) in Inter Partes Reexamination Control No. 95/000,666.

On March 12, 2012, Butamax filed a complaint in the Delaware District Court, as Case No. 1:12-cv-00298-SLR, alleging that the Company is infringing one or more claims made in U.S. Patent No. 8,129,162, entitled “Ketol-Acid Reductoisomerase Using NADH.” This complaint is in addition to the Amended Complaint discussed above. Butamax is seeking a declaratory judgment, injunctive relief, damages, interest, costs and expenses, including attorney’s fees. The Company believes that it has meritorious defenses to these allegations and intends to vigorously defend this lawsuit. This case is scheduled for trial on April 25, 2016.

On March 13, 2012, the Company filed a complaint in the Delaware District Court, as Case No. 1:12-cv-00301-SLR, alleging that Butamax and DuPont are infringing U.S. Patent No. 8,133,715 (the “’715 Patent”), entitled “Reduced By-Product Accumulation for Improved Production of Isobutanol.” The ’715 Patent claims recombinant microorganisms, including yeast, with modifications for the improved production of isobutanol. The Company is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses.

On April 10, 2012, the Company filed a complaint (the “Gevo Complaint”) in the Delaware District Court, as Case No. 1:12-cv-00448-SLR, alleging that Butamax and DuPont are infringing one or more claims made in U.S. Patent No. 8,153,415 (the “’415 Patent”) entitled “Reduced By-Product Accumulation for Improved Production of Isobutanol.” The ’415 Patent claims technology which eliminates two pathways that compete for isobutanol pathway intermediates in yeast. The Company is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses.

On April 17, 2012, the Company amended the Gevo Complaint to include allegations that Butamax and DuPont are infringing one or more claims made in U.S. Patent No. 8,158,404 (the “’404 Patent”) entitled “Reduced By-Product Accumulation for Improved Production of Isobutanol.” The ’404 Patent claims the reduction or elimination of important enzymes in a pathway in isobutanol- producing yeast. The Company is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses.

On May 9, 2012, coordinated discovery was ordered for Case Nos. 1:12-cv-00070-SLR, 1:12-cv-00298-SLR, 1:12-cv-00301-SLR, and 1:12-cv-00448-SLR. By virtue of the same order, discovery in Case No. 1:12-cv-00602-SLR was also coordinated with these cases.

On May 15, 2012, Butamax filed a complaint in the Delaware District Court, as Case No. 1:12-cv-00602-SLR, alleging that the Company is infringing one or more claims made in U.S. Patent No. 8,178,328, entitled “Fermentive Production of Four Carbon Alcohols.” Butamax is seeking a declaratory judgment, injunctive relief, damages, interest, costs and expenses, including attorney’s fees. The Company believes that it has meritorious defenses to these allegations and intends to vigorously defend this lawsuit. This case is scheduled for trial on April 25, 2016.

On June 19, 2012, the Delaware District Court denied the motion for preliminary injunction which was filed by Butamax on September 22, 2011 with respect to the alleged infringement by the Company of one or more claims made in the ’889 Patent. As is normal and customary in patent infringement actions of this nature, Butamax then filed a notice of appeal. In connection with its appeal, Butamax also filed a motion with the Delaware District Court seeking a temporary order to limit the Company’s activities with respect to the automotive fuel blending market while Butamax appealed the denial of its motion for preliminary injunction.

On July 6, 2012, the Delaware District Court issued a temporary order which stated, in part, that the Company could not deliver, provide, distribute, ship, release or transfer in any way bio-isobutanol produced at the Agri-Energy Facility to any third party for any use or purpose related to the automotive fuel blending market while Butamax appealed the denial of its motion for preliminary injunction. The Company filed an appeal of the temporary order. Under the temporary order, the Company remained free to operate in markets such as chemicals, jet fuel, marine fuel and small engine fuel. On August 10, 2012, the Federal Circuit Court of Appeals granted the Company’s motion to stay the status quo order entered on July 6, 2012 by the Delaware District Court. On November 16, 2012, the Federal Circuit Court of Appeals affirmed the Delaware District Court’s denial of Butamax’s preliminary injunction motion.

On July 31, 2012, the Company filed a complaint in the United States District Court for the Eastern District of Texas, as Case No. 2:12-cv-00417, alleging that Butamax, DuPont, BP, BP Corporation North America Inc. and BP Biofuels North America LLC are infringing U.S. Patent No. 8,232,089 (the “’089 Patent), entitled “Cytosolic Isobutanol Pathway Localization for the Production of Isobutanol.” The Company is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. On December 17, 2012, this case was transferred to the Delaware District Court as Case No. 1:12-cv-01724-SLR. On February 19, 2013, BP filed a motion seeking to dismiss the Company’s complaint for failure to state a claim against it. On March 8, 2013, the Company filed a response in opposition to BP’s motion. On March 18, 2013, BP filed its reply brief, and the issue was submitted to the court for decision. On July 8, 2013, the court granted BP’s motion. Despite the court’s decision, Butamax, DuPont, BP Corporation North America Inc. and BP Biofuels North America LLC remain defendants in the suit.

On July 31, 2012, Butamax and DuPont filed a lawsuit in the Delaware District Court for declaratory judgment against the Company, as Case No. 1:12-cv-00999-SLR, seeking a judicial determination that the ’089 Patent is invalid and that Butamax and DuPont do not infringe it. On January 28, 2013, this case was closed following a voluntary stipulation of dismissal filed by both parties.

On August 6, 2012, Butamax filed a complaint in the Delaware District Court, as Case No. 1:12-cv-01014-SLR, alleging that the Company is infringing U.S. Patent No. 8,222,017, entitled “Ketol-Acid Reductoisomerase Using NADH.” Butamax is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. This case is scheduled for trial on April 25, 2016. On January 22, 2013, discovery in this case was consolidated with Case Nos. 1:12-cv-00070-SLR, 1:12-cv-00298-SLR, 1:12-cv-00301-SLR, 1:12-cv-00448-SLR, and 1:12-cv-00602-SLR. In December 2013, Gevo withdrew claims of infringement against Butamax in Case Nos. 1:12-cv-00301-SLR, and 1:12-cv-00448-SLR. Despite the withdrawal of the infringement claims by Gevo against Butamax in Case Nos. 1:12-cv-00301-SLR and 1:12-cv-00448-SLR, Butamax continues to pursue counterclaims of invalidity in these cases.

On August 14, 2012, the Company filed a lawsuit in the United States District Court for the Eastern District of Texas for declaratory judgment against Butamax, DuPont, BP, BP Corporation North America Inc. and BP Biofuels North America LLC, as Case No. 2:12-cv-00435, seeking a judicial determination that a recently issued Butamax U.S. Patent No. 8,241,878 (the “’878 Patent”), entitled “Recombinant Yeast Host Cell with Fe-S Cluster Proteins and Methods of Using Thereof” is invalid and that the Company does not infringe it. On December 17, 2012, this case was transferred to the Delaware District Court as Case No. 1:12-cv-01725-SLR. On January 28, 2013, this case was closed following a voluntary stipulation of dismissal filed by both parties.

On August 14, 2012, Butamax filed a complaint in the Delaware District Court, as Case No. 1:12-cv-01036-SLR, alleging that the Company is infringing the ’878 Patent. Butamax is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. This case is scheduled for trial on August 24, 2015.

On September 25, 2012, the Company filed a complaint in the Delaware District Court, as Case No. 1:12-cv-01202-SLR, alleging that Butamax and DuPont are infringing U.S. Patent No. 8,273,565 (the “’565 Patent”), entitled “Methods of Increasing Dihydroxy Acid Dehydratase Activity to Improve Production of Fuels, Chemicals, and Amino Acids.” The Company is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. On September 25, 2012, Butamax and DuPont filed a lawsuit in the Delaware District Court for declaratory judgment against the Company, as Case No. 1:12-cv-01201-SLR, seeking a judicial determination that the ’565 Patent is invalid and that Butamax and DuPont do not infringe it. On August 9, 2013, Case Nos. 1:12-cv-01202-SLR and 1:12-cv-01201-SLR were closed following a voluntary stipulation of dismissal filed by both parties.

On September 25, 2012, Butamax filed a complaint in the Delaware District Court, as Case No. 1:12-cv-01200-SLR, alleging that the Company is infringing U.S. Patent No. 8,273,558, entitled “Fermentive Production of Four Carbon Alcohols.” Butamax is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. This case is scheduled for trial on August 24, 2015.

On October 8, 2012, Butamax filed a complaint in the Delaware District Court, as Case No. 1:12-cv-01300-SLR, alleging that the Company is infringing U.S. Patent No. 8,283,144, entitled “Fermentive Production of Four Carbon Alcohols.” Butamax is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. This case is scheduled for trial on August 24, 2015.

On October 8, 2012, Butamax filed a lawsuit in the Delaware District Court for declaratory judgment against the Company, as Case No. 1:12-cv-01301-SLR, seeking a judicial determination that Butamax is not infringing the Company’s U.S. Patent No. 8,283,505, entitled “Recovery of Higher Alcohols from Dilute Aqueous Solutions.” On January 28, 2014 the Delaware District Court issued an order dismissing Case No. 1:12-cv-01301-SLR.

On February 13, 2013, coordinated discovery was ordered for Case Nos. 1:12-cv-01036-SLR, 1:12-cv-01200-SLR, 1:12-cv-01201-SLR, 1:12-cv-01202-SLR, 1:12-cv-01300-SLR, 1:12-cv-01301-SLR, and 1:12-cv-01724-SLR. Case Nos. 1:12-cv-01036-SLR, 1:12-cv-01200-SLR and 1:12-cv-01300-SLR are currently set for trial on August 24, 2015.

On March 19, 2013, the Delaware District Court issued an order regarding claim construction and summary judgment in the patent suit involving the ’188 Patent and the ’889 Patent. Both parties had asked the Delaware District Court to resolve certain issues regarding the ’188 Patent and the ’889 Patent without a trial by seeking summary judgment from the court. Butamax had filed a motion seeking summary judgment that the Company infringed such patents, but the Delaware District Court denied Butamax’s motion. The Company moved for summary judgment of noninfringement, both as a matter of literal infringement and infringement under the doctrine of equivalents, and the Delaware District Court granted the Company’s motion regarding doctrine of equivalents infringement. The Company also moved for summary judgment of invalidity of various claims in the ’188 Patent and the ’889 Patent. The Delaware District Court granted this motion in part, ruling that Butamax’s claims related to the inactivation of competing pathways for carbon flow were invalid.

The Delaware District Court also provided certain claim construction rulings, including a ruling that Butamax’s patent claims were limited to an “acetohydroxy acid isomeroreductase” enzyme that is “NADPH-dependent.” The remaining issues were to be resolved by a jury trial, scheduled to commence on April 1, 2013.

On March 20, 2013, the Delaware District Court held the final pre-trial hearing leading up to the trial on the ’188 Patent and the ’889 Patent scheduled to commence April 1, 2013. During the hearing, Butamax’s attorney acknowledged that the Company does not infringe such patents under the Delaware District Court’s construction of a key claim term in such patents, “acetohydroxy acid isomeroreductase.” Butamax offered to stipulate to no literal infringement under the Delaware District Court’s construction. In view of this stipulation and the Delaware District Court’s prior ruling of no infringement under Butamax’s alternative infringement theory, the doctrine of equivalents, on April 10, 2013 a judgment of no infringement was entered in favor of the Company.

On April 19, 2013, Butamax filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit to appeal the Delaware District Court’s Memorandum and Order of March 19, 2013, and the Delaware District Court’s Amended Final Judgment of April 10, 2013. Oral arguments for the Butamax appeal were heard by the U.S. Court of Appeals for the Federal Circuit on November 7, 2013.

On February 18, 2014, the U.S. Court of Appeals for the Federal Circuit vacated the Delaware District Court’s denial of Butamax’s motion for summary judgment of literal infringement of the asserted claims of the ’188 Patent and the ’889 Patent and remanded the question of infringement to the Delaware District Court for reconsideration under a revised claim construction. The U.S. Court of Appeals for the Federal Circuit also vacated and remanded the Delaware District Court’s grant of the Company’s motion for summary judgment of noninfringement under the doctrine of equivalents. The U.S. Court of Appeals for the Federal Circuit also reversed the Delaware District Court’s grant of the Company’s motion for summary judgment of invalidity for lack of a written description of claims 12 and 13 of the ’889 Patent and the Delaware District Court’s order that those same claims are invalid for lack of enablement. The remanded trial for the ’188 and ’889 patents in the Delaware District Court was scheduled to be held on July 21, 2014. On April 22, 2014, the Company filed a Petition for Writ of Certiorari with the U.S. Supreme Court to appeal the decision of the U.S. Court of Appeals for the Federal Circuit. On April 25, 2014, the Company filed a motion to stay the Delaware District Court’s July 21, 2014 trial pending the disposition of its Petition for Writ of Certiorari with the U.S. Supreme Court and any follow-on proceedings.

On July 11, 2014, the Delaware District Court granted the Company’s motion to stay the patent litigation on the ‘188 Patent and ‘889 Patent. The District Court’s decision postpones the trial in this action, which was scheduled to begin on July 21, 2014. The decision by the Delaware District Court was based on the status of our Petition for Writ of Certiorari with the U.S. Supreme Court. It appeared that the U.S. Supreme Court was holding the petition pending its decision in Teya Pharmaceuticals USA, Inc. v. Sandoz, Inc. (the “Teva Case”), a case with the potential to change the Federal Circuit’s standard of review of district court claim construction and ultimately negate jury verdicts obtained under the then-current interpretation of patent claims. Oral Argument in the Teva Case occurred on October 15, 2014 and on January 20, 2015, the U.S. Supreme Court ruled in Teva’s favor and determined that the Federal Circuit must now apply the “clear error” standard of review and cannot set aside District Courts’ findings of fact unless they were clearly erroneous. On January 26, 2015, the Supreme Court ruled in Gevo’s favor, vacated an earlier Federal Circuit Court ruling on the interpretation of key Butamax patent claims and remanded the case back to the Federal Circuit Court for consideration in light of the new “clear error” standard of appellate review that was decided in the Teva Case.”

On February 18, 2014, the Delaware District Court granted Gevo’s motion to stay the litigation regarding Gevo’s ’715 Patent, ’404 Patent and ’415 Patent pending the USPTO’s issuance of a Right to Appeal Notice during inter partes re-examination of those patents.

Due to the nature and stage of this litigation, the Company has determined that the possible loss or range of loss related to this litigation cannot be reasonably estimated at this time. The next Delaware District Court trial for the Butamax litigation is currently scheduled for August 24, 2015 and an additional trial is scheduled for April 25, 2016. The Company expects to continue to incur significant costs related to its involvement in the foregoing legal proceedings.

Leases. During the year ended December 31, 2012, the Company entered into a six year software license agreement. The Company concluded that the software license agreement qualifies as a capital lease. Accordingly, at December 31, 2014, the Company has capital lease liabilities of $0.1 million and $0.3 million included in accounts payable and accrued liabilities and other long-term liabilities, respectively on its consolidated balance sheets. At December 31, 2013, the Company has capital lease liabilities of $0.1 million and $0.4 million included in accounts payable and accrued liabilities and other long-term liabilities, respectively on its consolidated balance sheets.

The Company has an operating lease for its office, research, and production facility in Englewood, Colorado (the “Colorado Facility”) with a term expiring in July 2016. The Company also maintains a corporate apartment in Colorado, which has a lease term expiring during the next 12 months.

Rent expense for the years ended December 31, 2014, 2013 and 2012 was $0.5 million, $0.6 million and $0.6 million, respectively. The Company recognizes rent expense on its operating leases on a straight-line basis.

The table below shows the future minimum payments under non-cancelable operating leases and capital leases at December 31, 2014 (in thousands).

	Operating Leases		Capital Lease		Total Lease Payments
2015	$	1,826	$	157	$	1,983
2016		1,308		162		1,470
2017		1,044		167		1,211
2018		1,044		-		1,044
2019 and thereafter		529		-		529
Total	$	5,751	$	486	$	6,237

Indemnifications. In the ordinary course of its business, the Company makes certain indemnities under which it may be required to make payments in relation to certain transactions. As of December 31, 2014 and 2013, the Company did not have any liabilities associated with indemnities.

In addition, the Company, as permitted under Delaware law and in accordance with its amended and restated certificate of incorporation and amended and restated bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The duration of these indemnifications, commitments, and guarantees varies and, in certain cases, is indefinite. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable. No such losses have been recorded to date.

Environmental Liabilities. The Company’s operations are subject to environmental laws and regulations adopted by various governmental authorities in the jurisdictions in which it operates. These laws require the Company to investigate and remediate the effects of the release or disposal of materials at its locations. Accordingly, the Company has adopted policies, practices and procedures in the areas of pollution control, occupational health and the production, handling, storage and use of hazardous materials to prevent material environmental or other damage, and to limit the financial liability which could result from such events. Environmental liabilities are recorded when the Company’s liability is probable and the costs can be reasonably estimated. No environmental liabilities have been recorded as of December 31, 2014.

Fair Value Measurements and Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value Measurements and Fair Value of Financial Instruments

18. Fair Value Measurements and Fair Value of Financial Instruments

Accounting standards define fair value, outline a framework for measuring fair value, and detail the required disclosures about fair value measurements. Under these standards, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. Standards establish a hierarchy in determining the fair market value of an asset or liability. The fair value hierarchy has three levels of inputs, both observable and unobservable. Standards require the utilization of the highest possible level of input to determine fair value.

—	Level 1 – inputs include quoted market prices in an active market for identical assets or liabilities.

—

Level 2 – inputs are market data, other than Level 1, that are observable either directly or indirectly. Level 2 inputs include quoted market prices for similar assets or liabilities, quoted market prices in an inactive market, and other observable information that can be corroborated by market data.

—	Level 3 – inputs are unobservable and corroborated by little or no market data.

While the Company believes that its valuation methods, as set forth below, are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Inventories. The Company records its inventory, primarily corn inventory, at fair value only when the Company’s cost of corn purchased exceeds the market value for corn. The Company determines the market value of corn based upon Level 1 inputs using quoted market prices. During the years ended December 31, 2014, 2013 and 2012, the Company recognized $0.1 million, $0.8 million and $0.3 million, respectively, in write-downs of its corn inventory to market prices.

Derivative Assets and Liabilities. The fair value of exchange-traded derivative instruments held is based on Level 1 inputs using quoted market prices. The Company did not have any exchange-traded derivative instruments at December 31, 2014 or 2013.

Secured Debt. The Company has estimated the fair value of its secured debt obligations based upon discounted cash flows with Level 3 inputs, such as the terms that management believes would currently be available to the Company for similar issues of debt, taking into account the current credit risk of the Company and other market factors. In May 2014, the Company entered into an amended agreement with Triplepoint in which the loans outstanding were settled in exchange for a new loan with a May 2017 maturity date for $1.0 million which amortizes over 36 months and bears interest at a rate equal to 9% per annum. The Company has determined that the estimated fair value approximates book value as of December 31, 2014.

The following table sets forth the principal balance of the Company’s secured debt obligation and the associated estimated fair value at December 31, 2014 and 2013 (in thousands).

	2014				2013
Issuance	Principal Balance		Estimated Fair Value		Principal Balance		Estimated Fair Value
TriplePoint - May 2014 Advance	$	822	$	773	$	-	$	-
TriplePoint - January 2012 Advance		-		-		3,495		3,079
TriplePoint - October 2011 Advance		-		-		6,657		5,942
TriplePoint - September 2010 Advance		-		-		917		847

2017 Notes. The Company has estimated the fair value of the 2017 Notes, to be $25.5 million at December 31, 2014 based upon Level 2 inputs, including the market price of the Company’s common stock. The Company has valued the 2017 Notes and all of its components using the fair value option. See Note 8 for the fair value inputs used to estimate the fair value of the 2017 Notes. On the date of issuance in May 2014, the 2017 Notes were a term loan and recorded at fair value at that date.

2022 Notes Embedded Derivative. The Company has estimated the fair value of the 2022 Notes, including the embedded derivative, to be $19.4 million and $15.9 million at December 31, 2014 and 2013, respectively, based upon Level 2 inputs, including the market price of the 2022 Notes derived from actual trades of the 2022 Notes. The Company had estimated the fair value of the embedded derivative on a stand-alone basis to be $0.0 million and $3.5 million at December 31, 2014 and 2013, respectively, based upon Level 2 inputs. See Note 6 for the fair value inputs used to estimate the fair value of the 2022 Notes with and without the embedded derivative and the fair value of the embedded derivative.

Derivative Warrant Liability. In December 2013, the Company issued the 2013 Warrants to purchase 21,303,750 shares of the Company’s common stock. Based on the terms of the 2013 Warrants, the Company determined the 2013 Warrants qualified as a derivative and, as such, are presented as a derivative warrant liability on the consolidated balance sheets and recorded at fair value each reporting period. The Company determined the estimated fair value of the 2013 Warrants as of December 31, 2013 to be $7.2 million based upon Level 1 inputs, the quoted market prices of the 2013 Warrants on such date. The Company valued the 2013 Warrants on the date of issuance based upon Level 2 observable market prices, using the “with-and-without method,” where the value of the common stock including the 2013 Warrants is defined as the “with,” and the value of the common stock excluding the 2013 Warrants as traded on the NASDAQ market is defined as the “without.” This method estimates the value of the 2013 Warrants by looking at the difference in the values between the common stock with the 2013 Warrants and the value of the common stock without the 2013 Warrants. Based upon this method, the Company estimated the value of the 2013 Warrants to be $4.0 million on the date of issuance. The Company determined the estimated fair value of the 2013 Warrants as of December 31, 2014 to be $1.4 million based upon Level 2 inputs utilizing an analysis of actual historical market trades of the 2013 Warrants and a Black Scholes model. The Company relied on Level 2 inputs for estimating the fair value of the 2013 Warrants as of December 31, 2014 due to the lack of market trades of the 2013 Warrants on such date.

In August of 2014, the Company issued 2014 Warrants to purchase 15,000,000 shares of the Company’s common stock. Based on the terms of the 2014 Warrants, the Company determined the 2014 Warrants qualify as a derivative and, as such, are presented as a derivative warrant liability on the consolidated balance sheets and recorded at fair value each reporting period. The Company determined the estimated fair value of the 2014 Warrants as of December 31, 2014 to be $1.7 million based upon Level 2 inputs utilizing an analysis of actual historical market trades of the 2014 Warrants. The Company relied on Level 2 inputs for estimating the fair value of the 2014 Warrants as of December 31, 2014 due to the lack of market trades of the 2014 Warrants on such date.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Segments

12 Months Ended

Dec. 31, 2014

Segment Reporting [Abstract]

Segments

19. Segments

The Company’s chief operating decision maker is provided with and reviews the financial results of each of the Company’s consolidated legal entities, Gevo, Inc., Gevo Development, LLC, and Agri-Energy, LLC. The Company organizes its business segments based on the nature of the products and services offered through each of its consolidated legal entities. All revenue is earned, and all assets are held, in the U.S.

The following table sets forth our financial results by segment (in thousands).

	Year Ended December 31,
	2014			2013			2012
Revenues:
Gevo	$	4,718		$	4,822		$	3,505
Gevo Development / Agri-Energy		23,548			3,402			20,880
Consolidated	$	28,266		$	8,224		$	24,385

Loss from operations:
Gevo	$	(26,567	)	$	(39,745	)	$	(58,837	)
Gevo Development / Agri-Energy		(13,210	)		(15,770	)		(12,600	)
Consolidated	$	(39,777	)	$	(55,515	)	$	(71,437	)

Interest expense:
Gevo	$	10,446		$	5,815		$	3,051
Gevo Development / Agri-Energy		1,578			3,486			3,287
Consolidated	$	12,024		$	9,301		$	6,338

Depreciation expense:
Gevo	$	937		$	1,160		$	1,200
Gevo Development / Agri-Energy		3,943			2,233			2,113
Consolidated	$	4,880		$	3,393		$	3,313

Acquisitions of plant, property and equipment:
Gevo	$	116		$	591		$	2,204
Gevo Development / Agri-Energy		4,778			9,215			50,228
Consolidated	$	4,894		$	9,806		$	52,432

	December 31,
	2014			2013
Total assets:
Gevo	$	95,680		$	100,888
Gevo Development / Agri-Energy		49,961			65,281
Intercompany eliminations		(46,713	)		(49,814	)
Consolidated	$	98,928		$	116,355

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	20. Subsequent Events Public Offering of Common Stock and Warrants On February 3, 2015, the Company closed the sale of 33,250,000 common stock units. Each common stock unit consists of one share of common stock, a Series A warrant to purchase one share of common stock and a Series B warrant to purchase one share of common stock at a public offering price of $0.20 per common stock unit. The Series A warrants have an exercise price of $0.27 per share, are exercisable from the date of original issuance and will expire on February 3, 2020. The Series B warrants have an exercise price of $0.20 per share, are exercisable from the date of original issuance and will expire on August 3, 2015. The shares of common stock and the warrants are separable and were issued separately. The gross proceeds are approximately $6.7 million not including any future proceeds from the exercise of the warrants. Transfer of Common Stock Listing to the NASDAQ Capital Market On June 30, 2014, the Company received a deficiency letter from the Listing Qualifications Department of The NASDAQ Stock Market, notifying it that, for the prior 30 consecutive business days, the closing bid price of the Company’s common stock was not maintained at the minimum required closing bid price of at least $1.00 per share as required for continued listing on the NASDAQ Global Market. As part of the Company’s efforts to regain compliance with this requirement, the listing of the Company’s common stock was transferred from the NASDAQ Global Market to the NASDAQ Capital Market effective January 5, 2015. The transfer of the listing of the Company’s common stock to the NASDAQ Capital Market is not expected to have any impact on the trading in its common stock, and its common stock continues to trade under the symbol “GEVO.” By transferring its common stock listing from the NASDAQ Global Market to the NASDAQ Capital Market, the Company received an additional 180 calendar day compliance period, or until June 29, 2015, to regain compliance with the minimum $1.00 per share requirement for continued listing on the NASDAQ Capital Market. The Company intends to monitor the bid price of its common stock and its minimum market value of listed securities and will consider options available to it to achieve compliance, including potentially implementing a reverse stock split of the outstanding shares of the Company’s common stock. Filing of a Preliminary Proxy to Call a Special Meeting of Stockholders On February 23, 2015, the Company filed a preliminary proxy to call a special meeting (the “Special Meeting”) of stockholders of Gevo, Inc., to be held on Monday, April 13, 2015, at the Company’s offices in Englewood, Colorado. The Special Meeting will be held to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of the Company’s common stock, by a ratio of not less than one-for-ten and not more than one-for-thirty at any time on or prior to June 27, 2015, with the exact ratio to be set at a whole number within this range by the Board of Directors of the Company in its sole discretion.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Nature of Business

Nature of Business. Gevo, Inc. (“Gevo” or the “Company,” which, unless otherwise indicated, refers to Gevo, Inc. and its subsidiaries) is a renewable chemicals and next generation biofuels company focused on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Gevo, Inc. was incorporated in Delaware on June 9, 2005. Gevo, Inc. formed Gevo Development, LLC (“Gevo Development”) in September 2009 to finance and develop biorefineries through joint venture, licensing arrangements, tolling arrangements or direct acquisition (see Note 13 for more information on Gevo Development). Gevo Development became a wholly-owned subsidiary of the Company in September 2010. Gevo Development purchased Agri-Energy, LLC (“Agri-Energy”) in September 2010. Through May 2012, Agri-Energy, a wholly-owned subsidiary of Gevo Development, was engaged in the business of producing and selling ethanol and related products produced at its plant located in Luverne, Minnesota (the “Agri-Energy Facility”). The Company commenced the retrofit of the Agri-Energy Facility in 2011 and commenced initial startup operations for the production of isobutanol at this facility in May 2012. In September 2012, the Company made the strategic decision to pause isobutanol production at the Agri-Energy Facility to focus on optimizing specific parts of the process to further enhance isobutanol production rates. In 2013, the Company modified the Agri-Energy Facility in order to increase the isobutanol production rate. In June 2013, the Company resumed the limited production of isobutanol, operating one fermenter and one Gevo Integrated Fermentation Technology^® (“GIFT^®”) separation system in order to (i) verify that the modifications had significantly reduced the previously identified infections, (ii) demonstrate that its biocatalyst performs in the one million liter fermenters at the Agri-Energy Facility, and (iii) confirm GIFT^® efficacy at commercial scale at the Agri-Energy Facility. In August 2013, the Company expanded production capacity at the Agri-Energy Facility by adding a second fermenter and second GIFT^® system to further verify its results with a second configuration of equipment. In October 2013, the Company began commissioning the Agri-Energy Facility on corn mash to test isobutanol production run rates and to optimize biocatalyst production, fermentation separation and water management systems. In March 2014, the Company decided to leverage the flexibility of its GIFT^® technology and make further modifications the Agri-Energy Facility which it believed would enable the simultaneous production of isobutanol and ethanol. In July 2014, the Company began more consistent co-production of isobutanol and ethanol at the Agri-Energy Facility, with one fermenter utilized for isobutanol production and three fermenters utilized for ethanol production. In line with the Company’s strategy to maximize asset utilization and site cash flows, the Company believes that this configuration of the plant should allow it to continue to optimize its isobutanol technology at a commercial scale, while taking advantage of potentially superior ethanol contribution margins.

As of December 31, 2014, the Company continues to engage in research and development, business development, business and financial planning, and to optimize operations for isobutanol and ethanol production at the Agri-Energy Facility and raise capital. Ultimately, the Company believes that the attainment of profitable operations is dependent upon future events, including (i) completing its development activities resulting in commercial production and sales of isobutanol or isobutanol-derived products and/or technology, (ii) obtaining adequate financing to complete its development activities, (iii) obtaining adequate financing to build out further isobutanol production capacity, (iv) gaining market acceptance and demand for its products and services, and attracting and (v) retaining qualified personnel.

The Company has primarily derived revenue from the sale of ethanol, distiller’s grains and other related products produced as part of the ethanol production process at the Agri-Energy Facility. The production of ethanol alone is not the Company’s intended business and its future strategy is expected to depend on its ability to produce and market isobutanol and products derived from isobutanol. Given that the production of ethanol alone is not the Company’s intended business, and the Company is only beginning to achieve more consistent production and revenue from the sale of isobutanol, the historical operating results of Agri-Energy may not be indicative of future operating results for Agri-Energy or Gevo.

Financial Condition

Financial Condition. For the year ended December 31, 2014, the Company incurred a consolidated net loss of $41.1 million and had an accumulated deficit of $303.3 million. The Company’s cash and cash equivalents at December 31, 2014 totaled $6.4 million which is primarily being used for the following: (i) operating activities and completion of the side-by-side configuration of the Agri-Energy Facility; ii) operating activities at its corporate headquarters in Colorado, including research and development work; (iii) capital improvements primarily associated with its Agri-Energy Facility; (iv) costs associated with optimizing isobutanol production technology; (v) costs associated with the ongoing litigation with Butamax Advanced Biofuels LLC (“Butamax”), a joint venture vetween BP p.l.c. (“BP”) and E. I. du Pont de Nemours and Company (“DuPont”); and (vi) debt service obligations. The Company expects to incur future net losses as it continues to fund the development and commercialization of its product candidates. The Company’s transition to profitability is dependent upon, among other things, the successful development and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability or positive cash flows, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, the Company may seek additional capital through arrangements with strategic partners or from other sources, it may seek to restructure its secured debt and it will continue to address its cost structure. Notwithstanding, there can be no assurance that the Company will be able to raise additional funds, or achieve or sustain profitability or positive cash flows from operations. Based on the Company’s operating plan, existing working capital at December 31, 2014 was not sufficient to meet the cash requirements to fund planned operations through December 31, 2015 without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern at December 31, 2014. The Company’s inability to continue as a going concern may potentially affect the Company’s rights and obligations under its Senior Secured Debt, Secured Debt and Convertible Notes. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. See Note 8 for information on the Company’s debt obligations and see Note 20 for information on the Company’s issuance of common stock units subsequent to December 31, 2014.

Despite the Company’s continued success in meeting isobutanol fermentation targets, producing isobutanol and ethanol simultaneously, and its progress toward achieving breakeven earnings before interest, taxes, depreciation and amortization (EBITDA) at the Agri-Energy Facility, the Company continues to face significant expenses related to its ongoing litigation with Butamax. While the U.S. Supreme Court recently ruled in the Company’s favor and overturned an earlier Federal Circuit Court of Appeals ruling on the interpretation of key claims related to certain patents, trials related to other patents were recently scheduled for August 2015 and April 2016 and the Company expects to incur significant costs preparing for and participating in these upcoming trials. The Company continues to believe that the Butamax complaints are without merit. However, if it is unable to raise the significant funds that will be required for it to continue to defend intellectual property rights, the Company could be forced to change its business strategy which may include one or more of the following: (i) terminating the research and development, manufacture, sale and use of products that include the subject intellectual property; (ii) conducting research and development and manufacturing any products that include the subject intellectual property outside of the U.S.; (iii) shifting its focus to the production of ethanol and/or the development of hydrocarbon products, including those that can be produced from ethanol; or (iv) pursuing strategic alternatives, including the monetization of some or all of the Company’s assets, in order to maximize stockholder value.

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Principles of Consolidation

Use of Estimates

Concentrations of Credit Risk

Cash and Cash Equivalents

Accounts Receivable

Inventories

Restricted Deposits

Restricted Deposits. The Company maintains a restricted deposit related to the 2017 Notes (defined below) that is equivalent to ten percent of the principal balance.

Derivative Instruments

The Company records realized and unrealized gains or losses on its derivative instruments as a component of cost of goods sold in the consolidated statements of operations.

The following table summarizes the realized and unrealized gains/ (losses) of the Company’s derivative instruments (in thousands).

	Year Ended December 31,
	2014		2013			2012
Realized Gain / (Losses)
Exchange-traded futures contracts	$	-	$	642		$	(375	)

Unrealized Gain / (Losses)
Exchange-traded futures contracts		-		(271	)		457
Forward purchase contracts		-		12			(12	)

Property, Plant and Equipment

Impairment of Property, Plant and Equipment

—	sales price of isobutanol and by-products such as dried distiller’s grains;

—	purchase price of corn;

—	production levels of isobutanol;

—	capital and operating costs to produce isobutanol; and

—	estimated useful life of the primary asset.

Factors which can impact these assumptions include, but are not limited to;

—	effectiveness of the Company’s technology to produce isobutanol at targeted margins;

—	demand for isobutanol and oil prices; and

—	harvest levels of corn.

Debt at Fair Value Option

Research and Development

Income Taxes

Stock-Based Compensation

Net Loss Per Share

	Year Ended December 31,
	2014		2013		2012
Warrants to purchase common stock		37,563,548		22,563,748		1,229,998
Convertible 2017 notes		22,537,983		-		-
Convertible 2022 notes		4,725,516		4,725,514		7,905,137
Outstanding options to purchase common stock		3,673,539		2,871,563		2,940,352
Unvested restricted common stock		875,265		791,389		183,416
Total		69,375,851		30,952,214		12,258,903

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2014

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Unrealized Gains/(Losses) of Derivative Instruments

The following table summarizes the realized and unrealized gains/ (losses) of the Company’s derivative instruments (in thousands).

	Year Ended December 31,
	2014		2013			2012
Realized Gain / (Losses)
Exchange-traded futures contracts	$	-	$	642		$	(375	)

Unrealized Gain / (Losses)
Exchange-traded futures contracts		-		(271	)		457
Forward purchase contracts		-		12			(12	)

Securities that Potentially Dilute the Calculation of Diluted Earnings Per Share

	Year Ended December 31,
	2014		2013		2012
Warrants to purchase common stock		37,563,548		22,563,748		1,229,998
Convertible 2017 notes		22,537,983		-		-
Convertible 2022 notes		4,725,516		4,725,514		7,905,137
Outstanding options to purchase common stock		3,673,539		2,871,563		2,940,352
Unvested restricted common stock		875,265		791,389		183,416
Total		69,375,851		30,952,214		12,258,903

Inventories (Tables)

12 Months Ended

Dec. 31, 2014

Inventory Disclosure [Abstract]

Components of Inventory Balances

The following table sets forth the components of the Company’s inventory balances (in thousands).

	December 31,
	2014		2013
Raw materials
Corn	$	1,369	$	1,456
Enzymes and other inputs		354		514
Finished goods		515		192
Work in process		610		224
Spare parts		1,444		1,195

Total inventories	$	4,292	$	3,581

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2014

Property Plant And Equipment [Abstract]

Property, Plant and Equipment by Classification

The following table sets forth the Company’s property, plant and equipment by classification (in thousands).

		December 31,
		2014			2013
Construction in progress	-	$	440		$	66,033
Plant machinery and equipment	10 years		13,367			11,009
Site improvements	10 years		7,015			7,007
Retrofit asset	20 years		65,601			-
Lab equipment, furniture and fixtures and vehicles	5 years		6,385			6,303
Demonstration plant	2 years		3,597			3,597
Buildings	10 years		2,543			2,543
Computer, office equipment and software	3 years		1,490			1,437
Leasehold improvements, pilot plant, land and support equipment	2 - 5 years		2,144			2,105
Total property, plant and equipment			102,582			100,034
Less accumulated depreciation and amortization			(21,342	)		(16,559	)

Property, plant and equipment, net		$	81,240		$	83,475

Accounts Payable and Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2014

Payables And Accruals [Abstract]

Components of Accounts Payable and Accrued Liabilities in Consolidated Balance Sheets

The following table sets forth the components of the Company’s accounts payable and accrued liabilities in the consolidated balance sheets (in thousands).

	December 31,
	2014		2013
Accounts payable - trade	$	2,639	$	6,460
Accrued legal-related fees		2,944		2,999
Deferred revenue		-		1,000
Accrued employee compensation		801		818
Other accrued liabilities		2,204		1,753

Total accounts payable and accrued liabilities	$	8,588	$	13,030

Embedded Derivatives (Tables)

12 Months Ended

Dec. 31, 2014

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Input to Lattice Model that was Used to Value Embedded Derivative

The following table sets forth the inputs (Level 2 as defined in Note 18) to the lattice model that were used to value the embedded derivatives.

	December 31,
	2014			2013
Stock price	$	0.32		$	1.43
Conversion Rate		175.6697			175.6697
Conversion Price	$	5.69		$	5.69
Maturity date	July 1, 2022			July 1, 2022
Risk-free interest rate		2.0	%		2.8	%
Estimated stock volatility		87	%		65	%
Estimated credit spread		20	%		33	%

2022 Notes With and Without Embedded Derivative and Fair Value of Embedded Derivative

The following table sets forth the value of the 2022 Notes with and without the embedded derivatives, and the fair value of the embedded derivatives (in thousands).

	December 31,
	2014		2013
Fair value of 2022 Notes:
With the embedded derivative	$	19,449	$	15,925
Without the embedded derivative		19,449		12,455
Estimated fair value of the embedded derivative	$	-	$	3,470

Secured Debt and Convertible Notes (Tables)

12 Months Ended

Dec. 31, 2014

Debt Instrument [Line Items]

Inputs to Lattice Model used to Value Term Loan and 2017 Notes for which Fair Value Option was Elected

The following table sets forth the inputs to the lattice model that were used to value the Term Loan and 2017 Notes for which the fair value option was elected.

	December 31,
	2014
Stock price	$	0.34
Conversion Rate		863.3
Conversion Price	$	1.16
Maturity date	March 15, 2017
Risk-free interest rate		0.80	%
Estimated stock volatility		85.0	%
Estimated credit spread		15.0	%

Information Pertaining to Convertible Notes

The following table sets forth information pertaining to the Term Loan and 2017 Notes which is included in the Company’s consolidated balance sheets (in thousands).

	Principal Amount of Term Loans			Principal Amount of 2017 Notes		Change in Estimated Fair Value			Total
Balance - December 31, 2013	$	-		$	-	$	-		$	-
Issuance of Term Loan		25,907			-		-			25,907
Exchange of Term Loan for 2017 Notes		(25,907	)		25,907		-			-
Non-cash paid-in-kind interest expense		-			201		-			201
Gain from change in fair value of debt		-			-		(648	)		(648	)
Balance - December 31, 2014	$	-		$	26,108	$	(648	)	$	25,460

Secured Debt Included in Consolidated Balance Sheets

	December 31,
	2014			2013
Secured debt
TriplePoint - September 2010 Advance	$	-		$	917
TriplePoint - October 2011 Advance		-			6,657
TriplePoint - January 2012 Advance		-			3,495
TriplePoint - Matures May 2017		822			-
Total secured debt		822			11,069
Less:
Unamortized debt discounts		(49	)		(942	)
		773			10,127
Less current portion of debt		(288	)		(788	)
Long-term portion of debt	$	485		$	9,339

Obligations by Year Relating to Secured Debt and Convertible Notes

The following sets forth the Company’s obligations to repay principal by year relating to its secured debt with TriplePoint and the Convertible Notes at December 31, 2014 (in thousands).

	Amount
2015	$	319
2016		348
2017		26,263
2018		-
2019 and thereafter		26,900

Total	$	53,830

2022 Notes

Debt Instrument [Line Items]

Information Pertaining to Convertible Notes

The following table sets forth information pertaining to the 2022 Notes which is included in the Company’s consolidated balance sheets (in thousands).

	Embedded Derivatives			Principal Amount of 2022 Notes			Debt Discount			Total
Balance - December 31, 2012	$	11,000		$	45,000		$	(30,446	)	$	25,554
Amortization of debt discount		-			-			3,300			3,300
Write-off of debt discount associated with conversion of debt		-			-			11,277			11,277
Gain from change in fair value of embedded derivatives		(3,114	)		-			-			(3,114	)
Conversion		(4,416	)		(18,100	)		-			(22,516	)
Balance - December 31, 2013	$	3,470		$	26,900		$	(15,869	)	$	14,501
Amortization of debt discount		-			-			2,648			2,648
Gain from change in fair value of embedded derivatives		(3,470	)		-			-			(3,470	)
Balance - December 31, 2014	$	-		$	26,900		$	(13,221	)	$	13,679

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

+ Details

Capital Stock (Tables)

12 Months Ended

Dec. 31, 2014

Stockholders Equity Note [Abstract]

Warrants to Purchase Shares of Common Stock Outstanding

The following table sets forth a summary of outstanding warrants to purchase shares of the Company’s common stock as of December 31, 2014.

	Issue Date	Expiration Date	Outstanding		Exercise Price
Common Stock Warrants	December 2013	December 2018		21,303,550	$	1.43
Common Stock Warrants	August 2014	August 2019		15,000,000	$	0.85
CDP Gevo, LLC	September 2009	September 2016		812,771	$	2.70
TriplePoint Capital LLC	August 2010	August 2017		199,999	$	1.18
TriplePoint Capital LLC	October 2011	October 2018		157,035	$	1.18
TriplePoint Capital LLC	January 2012	October 2018		31,407	$	1.18
Genesis Select	June 2013	June 2018		30,000	$	1.63
Virgin Green Fund I, L.P.	January 2008	February 2016		28,786	$	5.48
Total				37,563,548

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2014

Share Based Compensation [Abstract]

Stock-Based Compensation Expense

Stock-Based Compensation Expense. The following table sets forth the Company’s stock-based compensation expense (in thousands).

	Year Ended December 31,
	2014		2013		2012
Stock options and ESPP awards
Research and development	$	303	$	640	$	808
Selling, general and administrative		837		1,837		2,628

Restricted stock awards
Research and development		487		14		328
Selling, general and administrative		1,233		1,381		1,599

Warrants issued
Selling, general and administrative		-		39		2,616
Non-cash stock-based compensation		2,860		3,911		7,979

Modified stock option awards
Selling, general and administrative		-		-		890

Purchase of Class B interests of Gevo Development from CDP for cash
Selling, general and administrative		-		-		74
Cash stock-based compensation		-		-		964

Total stock-based compensation	$	2,860	$	3,911	$	8,943

Weighted-Average Assumptions Used to Estimate Fair Values for Stock Options Granted Using Black-Scholes Option Pricing Model

Determining Fair Value of Share-Based Payment Awards. The following table sets forth the Black-Scholes option pricing model assumptions and resulting grant date fair value for stock options granted.

	Year Ended December 31,
	2014			2013			2012

Risk-free interest rate		1.74	%		1.26	%		1.17	%
Expected dividend yield	None			None			None
Expected volatility factor		71.13	%		71.96	%		78.86	%
Expected option life (in years)		5.75		5.8			5.78
Weighted average grant date fair value	$	0.89		$	1.18		$	4.74

Stock Option Award Activity

Stock Option Award Activity. Stock option activity under the Company’s option plans at December 31, 2013 and changes during the year ended December 31, 2014 were as follows.

						Weighted-
						Average
				Weighted-		Remaining
				Average		Contractual
	Number of			Exercise		Term		Aggregate
	Options			Price		(years)		Intrinsic Value
Options outstanding at December 31, 2013		2,871,563		$	5.15	6.57		$	478
Granted		1,128,536			1.40
Canceled or forfeited		(470,686	)		6.90
Exercised		(5,000	)		0.47
Options outstanding at December 31, 2014		3,524,413		$	3.72	5.61		$	-

Options exercisable at December 31, 2014		2,532,633		$	4.54		5.16	$	-

Options vested and expected to vest at December 31, 2014		3,519,749		$	3.72		5.61	$	-

Summary of Information Associated with Outstanding and Exercisable Stock Options

The following table summarizes information associated with outstanding and exercisable stock options at December 31, 2014.

	Options Outstanding						Options Exercisable
					Weighted-						Weighted-
					Average				Weighted-		Average
Range of			Weighted-		Remaining				Average		Remaining
Exercise	Number of		Average Exercise		Contractual Life		Number of		Exercise		Contractual Life
Prices	Options		Price		in Years		Options		Price		in Years
$0.46 to $0.49		377,533	$	0.46		2.35		377,533	$	0.46		2.35
$0.50 to $0.99		76,030	$	0.88		9.48		12,700	$	0.88		9.46
$1.00 to $1.89		1,847,752	$	1.48		7.52		948,553	$	1.43		6.13
$2.70 to $8.73		582,590	$	2.88		5.00		567,502	$	2.87		4.94
$9.41 to $9.57		210,466	$	9.41		6.55		196,303	$	9.41		6.51
$9.57 to $12.67		354,906	$	10.40		4.73		354,906	$	10.40		4.73
$14.81 to $19.14		224,262	$	17.17		5.58		224,262	$	17.27		5.58

Non-Vested Restricted Stock Awards and Changes

Non-vested restricted stock awards at December 31, 2013 and changes during the year ended December 31, 2014 were as follows.

				Weighted-
				Average
	Number of			Grant-Date
	Shares			Fair Value
Non-vested at December 31, 2013		791,389		$	2.52
Granted		1,138,081			0.69
Vested		(983,530	)		1.54
Canceled or forfeited		(70,675	)		1.83
Non-vested at December 31, 2014		875,265		$	1.30

Gevo Development (Tables)

12 Months Ended

Dec. 31, 2014

Equity [Abstract]

Net Loss Incurred by Gevo Development

	Year Ended December 31,
	2014			2013			2012
Gevo Development Net Loss	$	(14,778	)	$	(19,243	)	$	(15,870	)

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Tax Effects of Temporary Differences that Give Rise to Net Deferred Tax Assets

The following table sets forth the tax effects of temporary differences that give rise to significant portions of the Company’s net deferred tax assets (in thousands).

	December 31,
	2014			2013
Deferred tax assets:
Net operating loss carryforwards	$	115,870		$	96,748
Research and other credits		6,047			5,502
Other temporary differences		(2,478	)		2,768
Deferred tax assets - before valuation allowance		119,439			105,018
Valuation allowance		(119,439	)		(105,018	)
Net deferred tax assets - after valuation allowance	$	-		$	-

Reconciling Items from Income Tax Computed at Statutory Federal Rate

The following table sets forth reconciling items from income tax computed at the statutory federal rate.

	Year Ended December 31,
	2014			2013			2012
Federal income tax at statutory rate		35.0	%		35.0	%		35.0	%
State income taxes, net of federal benefits		4.5	%		5.7	%		6.2	%
Research and other credits		-1.3	%		-2.2	%		0.0	%
Permanent deductions		-2.2	%		-1.5	%		-2.5	%
Valuation allowance		-36.0	%		-37.0	%		-38.7	%

Effective tax rate		0.0	%		0.0	%		0.0	%

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2014

Commitments And Contingencies Disclosure [Abstract]

Future Minimum Payments Under Non-cancelable Operating Leases

The table below shows the future minimum payments under non-cancelable operating leases and capital leases at December 31, 2014 (in thousands).

	Operating Leases		Capital Lease		Total Lease Payments
2015	$	1,826	$	157	$	1,983
2016		1,308		162		1,470
2017		1,044		167		1,211
2018		1,044		-		1,044
2019 and thereafter		529		-		529
Total	$	5,751	$	486	$	6,237

Fair Value Measurements and Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Estimate of Fair Value of Secured Debt Obligations

	2014				2013
Issuance	Principal Balance		Estimated Fair Value		Principal Balance		Estimated Fair Value
TriplePoint - May 2014 Advance	$	822	$	773	$	-	$	-
TriplePoint - January 2012 Advance		-		-		3,495		3,079
TriplePoint - October 2011 Advance		-		-		6,657		5,942
TriplePoint - September 2010 Advance		-		-		917		847

Segments (Tables)

12 Months Ended

Dec. 31, 2014

Segment Reporting [Abstract]

Summary of Segment Information

The Company organizes its business segments based on the nature of the products and services offered through each of its consolidated legal entities. All revenue is earned, and all assets are held, in the U.S.

The following table sets forth our financial results by segment (in thousands).

	Year Ended December 31,
	2014			2013			2012
Revenues:
Gevo	$	4,718		$	4,822		$	3,505
Gevo Development / Agri-Energy		23,548			3,402			20,880
Consolidated	$	28,266		$	8,224		$	24,385

Loss from operations:
Gevo	$	(26,567	)	$	(39,745	)	$	(58,837	)
Gevo Development / Agri-Energy		(13,210	)		(15,770	)		(12,600	)
Consolidated	$	(39,777	)	$	(55,515	)	$	(71,437	)

Interest expense:
Gevo	$	10,446		$	5,815		$	3,051
Gevo Development / Agri-Energy		1,578			3,486			3,287
Consolidated	$	12,024		$	9,301		$	6,338

Depreciation expense:
Gevo	$	937		$	1,160		$	1,200
Gevo Development / Agri-Energy		3,943			2,233			2,113
Consolidated	$	4,880		$	3,393		$	3,313

Acquisitions of plant, property and equipment:
Gevo	$	116		$	591		$	2,204
Gevo Development / Agri-Energy		4,778			9,215			50,228
Consolidated	$	4,894		$	9,806		$	52,432

	December 31,
	2014			2013
Total assets:
Gevo	$	95,680		$	100,888
Gevo Development / Agri-Energy		49,961			65,281
Intercompany eliminations		(46,713	)		(49,814	)
Consolidated	$	98,928		$	116,355

Nature of Business and Financial Condition - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 16, 2013	Dec. 31, 2011
Accounting Policies [Abstract]
Net loss	$ (41,145)	$ (66,806)	$ (60,712)
Deficit accumulated	(303,298)	(262,153)
Cash and cash equivalents	$ 6,359	$ 24,625	$ 66,744	$ 24,625	$ 94,225

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Summary Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary Of Significant Accounting Policies [Line Items]
Allowance for doubtful accounts	$ 0	$ 0
Restricted Deposits	10.00%
Interest incurred for capital projects	$ 1,800
Selling, general and administrative	18,341	25,548	$ 43,981
Deferred tax assets, Valuation Allowance	119,439	105,018
Patents
Summary Of Significant Accounting Policies [Line Items]
Selling, general and administrative	900	2,300	$ 2,700
Exchange Traded Futures
Summary Of Significant Accounting Policies [Line Items]
Margin deposits	$ 0	$ 0

Summary of Realized and Unrealized Gains/(Losses) of Derivative Instruments (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Derivative instruments, gain (loss)	$ (259)	$ 445
Realized Gain/(Loss) \| Exchange-traded futures contracts
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Derivative instruments, gain (loss)	642	(375)
Unrealized Gain / (Loss) \| Exchange-traded futures contracts
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Derivative instruments, gain (loss)	(271)	457
Unrealized Gain / (Loss) \| Forward purchase contracts
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Derivative instruments, gain (loss)	$ 12	$ (12)

Securities that Potentially Dilute Calculation of Diluted Earnings Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Warrants to purchase common stock	69,375,851	30,952,214	12,258,903
Warrants to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Warrants to purchase common stock	37,563,548	22,563,748	1,229,998
Convertible 2017 notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Warrants to purchase common stock	22,537,983
2022 Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Warrants to purchase common stock	4,725,516	4,725,514	7,905,137
Outstanding options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Warrants to purchase common stock	3,673,539	2,871,563	2,940,352
Unvested restricted common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Warrants to purchase common stock	875,265	791,389	183,416

Components of Inventory Balances (Detail) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Finished goods	$ 515	$ 192
Work in process	610	224
Spare parts	1,444	1,195
Total inventories	4,292	3,581
Corn
Inventory [Line Items]
Raw materials	1,369	1,456
Enzymes And Other Inputs
Inventory [Line Items]
Raw materials	$ 354	$ 514

Property, Plant and Equipment by Classification (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Property Plant And Equipment [Line Items]
Total property, plant and equipment		$ 102,582	$ 100,034
Less accumulated depreciation and amortization		(21,342)	(16,559)
Property, plant and equipment, net		$ 81,240	83,475
Construction in progress
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life
Total property, plant and equipment		$ 440	66,033
Plant machinery and equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life		10 years
Total property, plant and equipment		$ 13,367	11,009
Site improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life		10 years
Total property, plant and equipment		$ 7,015	7,007
Retrofit Asset
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life	20 years	20 years
Total property, plant and equipment		$ 65,601
Lab equipment, furniture and fixtures and vehicles
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life		5 years
Total property, plant and equipment		$ 6,385	6,303
Demonstration plant
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life		2 years
Total property, plant and equipment		$ 3,597	3,597
Buildings
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life		10 years
Total property, plant and equipment		$ 2,543	2,543
Computer, office equipment and software
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life		3 years
Total property, plant and equipment		$ 1,490	1,437
Leasehold improvements, pilot plant, land and support equipment
Property Plant And Equipment [Line Items]
Total property, plant and equipment		$ 2,144	$ 2,105
Leasehold improvements, pilot plant, land and support equipment \| Minimum
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life		2 years
Leasehold improvements, pilot plant, land and support equipment \| Maximum
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life		5 years

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property Plant And Equipment [Line Items]
Capitalized interest expense		$ 0	$ 200	$ 1,300
Amortization of capital lease asset		100	100	100
Depreciation and amortization		4,880	3,393	3,313
Depreciation expense in cost of goods sold		$ 4,000	2,100	$ 2,100
Retrofit Asset
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life	20 years	20 years
Computer, office equipment and software
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life		3 years
Capital lease		$ 700	$ 700

Components Accounts Payable and Accrued Liabilities in Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Payables And Accruals [Abstract]
Accounts payable - trade	$ 2,639	$ 6,460
Accrued legal-related fees	2,944	2,999
Deferred revenue		1,000
Accrued employee compensation	801	818
Other accrued liabilities	2,204	1,753
Total accounts payable and accrued liabilities	$ 8,588	$ 13,030

Embedded Derivatives - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Jul. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Derivative [Line Items]
Decrease in the estimated fair value of the embedded derivative		$ 3.5	$ 3.1	$ 17.0
2022 Notes
Derivative [Line Items]
Percentage of convertible senior notes embedded derivatives	7.50%
7.5% convertible senior notes, maturity date	2022
2022 notes, conversion date	Jul. 01, 2017	Jul. 01, 2017

Input to Lattice Model that was Used to Value Embedded Derivative (Detail)	12 Months Ended
	Dec. 31, 2014 $ / shares	Dec. 31, 2013 $ / shares	Aug. 31, 2014 $ / shares	Jul. 31, 2012 $ / shares	Feb. 14, 2011 $ / shares
Derivative [Line Items]
Stock price		$ 1.35	$ 0.60	$ 4.95	$ 15.00
Fair Value, Inputs, Level 2 \| 2022 Notes \| Embedded Derivative Financial Instruments
Derivative [Line Items]
Stock price	$ 0.32	$ 1.43
Conversion Rate	175.6697	175.6697
Conversion Price	$ 5.69	$ 5.69
Maturity date	Jul. 01, 2022	Jul. 01, 2022
Risk-free interest rate	2.00%	2.80%
Estimated stock volatility	87.00%	65.00%
Estimated credit spread	20.00%	33.00%

2022 Notes with and without Embedded Derivative and Fair Value of Embedded Derivative (Detail) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Fair value of 2022 Notes:
With the embedded derivative	$ 19,449	$ 15,925
Without the embedded derivative	$ 19,449	12,455
Estimated fair value of the embedded derivative		$ 3,470

Derivative Warrant Liability - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended			12 Months Ended
	Feb. 14, 2011	Aug. 31, 2014	Dec. 31, 2013	Jul. 31, 2012	Dec. 31, 2014	Dec. 31, 2013
Derivative [Line Items]
Common stock shares issued and sold	8,222,500	30,000,000		12,500,000		21,303,750
Warrant , Exercise Price					$ 1.18
Derivative warrant liability fair value			$ 7,243		$ 3,114	$ 7,243
Gain (loss) from change in fair value of derivative warrant liability					$ 6,530	$ (3,195)
2013 Warrants
Derivative [Line Items]
Common stock shares issued and sold			21,303,750
Warrant , Exercise Price					$ 1.43
Decreased Warrants Exercise Price					$ 1.02
Warrants expiration date					Dec. 16, 2018
2014 Warrants
Derivative [Line Items]
Warrant , Exercise Price					$ 0.85
Decreased Warrants Exercise Price					$ 0.64
Warrants expiration date					Aug. 05, 2019
Common Stock Units Issued		30,000,000
Additional purchase of common stock shares		15,000,000

Secured Debt and Convertible Notes - Additional Information (Detail)				1 Months Ended					12 Months Ended
	Mar. 27, 2015 USD ($)	Feb. 03, 2015 USD ($)	Feb. 14, 2011 USD ($)	Aug. 31, 2014 USD ($) shares	Jun. 30, 2014 USD ($) $ / shares	May 31, 2014 USD ($)	Dec. 31, 2013 USD ($) shares	Jul. 31, 2012 USD ($)	Dec. 31, 2014 USD ($) Installment Warrant $ / shares shares	Dec. 31, 2013 USD ($) shares	Dec. 31, 2012 USD ($)	Jan. 31, 2012 USD ($)	Oct. 31, 2011 USD ($)	Aug. 31, 2010 USD ($)
Debt Instrument [Line Items]
Debt issuance cost									$ 3,769,000
Debt instrument, interest rate									11.00%
Aggregate principal amount outstanding					10.00%
Restricted deposits									$ 2,611,000
Common stock, shares authorized \| shares							250,000,000		250,000,000	250,000,000
Estimated fair value of principal amount									$ 25,460,000
Interest expense									$ 8,255,000	$ 9,301,000	$ 6,338,000
End-of-term payment as percentage of amount borrowed								8.00%	5.75%
Proceeds from issuance of common stock and common stock units			$ 110,400,000	$ 2,400,000				$ 57,400,000	$ 18,000,000	28,761,000	61,875,000
Loan and security agreement outstanding principal amount							$ 5,100,000			5,100,000
Number of installments \| Installment									12
Debt Instrument, repurchase amount									$ 15,000,000			$ 5,000,000	$ 10,000,000
Number of warrants outstanding \| Warrant									3
Number of shares of common stock exercisable for warrants \| shares				0.5					388,411
Exercise price of common stock \| $ / shares									$ 1.18
Debt instrument, periodic payment, principal									$ 9,800,000
Long term borrowing interest rate									9.00%
Amortization period of interest expense									36 months
Proceeds from issuance of 2017 Notes, net											42,300,000
Non-cash interest expense									$ 7,860,000	4,719,000	2,207,000
Subsequent Event
Debt Instrument [Line Items]
Proceeds from issuance of common stock and common stock units		$ 6,700,000
First Installment
Debt Instrument [Line Items]
Outstanding principal amount of term loan					$ 25,900,000
Term Loans
Debt Instrument [Line Items]
Debt instrument, interest rate						15.00%			10.00%
Term Loans \| Interest Payable In Cash
Debt Instrument [Line Items]
Debt instrument, interest rate						5.00%			5.00%
Term Loans \| Interest Payable In Kind
Debt Instrument [Line Items]
Debt instrument, interest rate						10.00%			5.00%
Term Loans \| First Installment
Debt Instrument [Line Items]
Accrued paid in kind interest					$ 200,000
Gevo Loan
Debt Instrument [Line Items]
Outstanding principal amount of term loan														$ 5,000,000
Amended Agri Energy Loan Agreement
Debt Instrument [Line Items]
Debt instrument, additional term loan													$ 15,000,000
Amended Agri Energy Loan Agreement \| First Installment
Debt Instrument [Line Items]
Percentage of payment on principal amount and interest due									50.00%
Amended Agri Energy Loan Agreement \| Final Installment
Debt Instrument [Line Items]
Percentage of payment on principal amount and interest due									50.00%
Convertible 2017 notes
Debt Instrument [Line Items]
Debt instrument maturity date									Mar. 15, 2017
Convertible senior secured note, percentage of stock price						10.00%
Accrued paid in kind interest									$ 201,000
Conversion Price \| $ / shares					$ 1.1584
Debt Conversion, Description									The 2017 Notes have a conversion price (the “Conversion Price”) equal to $1.1584 per share or .8633 shares per $1 principal amount of 2017 Notes.
Conversion Rate									0.8633
Debt instrument, convertible, conversion price									$ 1,000
Number of consecutive trading days required for redemption									10 days
Excess to percentage of conversion price									150.00%
Repayment Terms									On January 29, 2015, we commenced a conversion forbearance period in accordance with the terms of the 2017 Notes during which neither the Company nor any holder of the 2017 Notes has the right to convert any principal amount of the 2017 Notes into shares of Common Stock. The conversion forbearance period will terminate when the Company provides notice to the trustee for the 2017 Notes that it has a sufficient number of authorized and unissued shares of Common Stock to permit conversion of all of the outstanding 2017 Notes. If, on June 27, 2015, the conversion forbearance period has not been terminated and we have failed to reserve out of our authorized but unissued shares or shares held in treasury, sufficient shares of Common Stock to provide for the conversion of all of the outstanding 2017 Notes, an event of default under the terms of the 2017 Notes will be triggered. Upon such occurrence, 100% of the principal amount and all accrued and unpaid interest under the 2017 Notes will become immediately due and payable.
Common stock, shares authorized \| shares									17,500,000
Estimated fair value of principal amount									$ 26,108,000
Convertible 2017 notes \| Fundamental Change
Debt Instrument [Line Items]
Percentage repurchase price									100.00%
Convertible 2017 notes \| Term Loans
Debt Instrument [Line Items]
Debt instrument maturity date									Mar. 15, 2017
Debt issuance cost									$ 1,500,000
Accrued paid in kind interest									$ 200,000
Conversion Rate									863.3
Debt instrument, face amount									$ 26,100,000
Estimated fair value of principal amount									25,500,000
Interest expense									$ 1,600,000
Convertible 2017 notes \| Term Loans \| Subsequent Event
Debt Instrument [Line Items]
Debt issuance cost	$ 600,000
2022 Notes
Debt Instrument [Line Items]
Debt instrument maturity date									Jul. 01, 2022
Debt issuance cost								$ 1,400,000
Convertible senior secured note, percentage of stock price									90.00%
Debt instrument, interest rate								7.50%
Conversion Price \| $ / shares									$ 5.69
Conversion Rate									175.6697
Debt instrument, convertible, conversion price									$ 1,000
Estimated fair value of principal amount							15,900,000		19,400,000	15,900,000
Interest expense									2,000,000	2,300,000	1,600,000
Proceeds from 2022 notes								$ 5,400,000
Percentage of convertible senior notes embedded derivatives								7.50%
Secured debt									$ 26,900,000
Amortization period of interest expense									5 years
Aggregate principal amount on sale of convertible notes								$ 45,000,000
Proceeds from issuance of 2017 Notes, net								$ 40,900,000
Non-cash interest expense									$ 2,800,000	$ 3,400,000	$ 400,000
Long term debt interest rate									40.00%
Amortization period of debt discount									5 years
2022 notes, conversion date								Jul. 01, 2017	Jul. 01, 2017
Discount rate used in computation of interest payment									2.00%
Number of trading days for valuation									10 days
Conversion of convertible debt to common stock									$ 18,100,000
Debt Conversion, Converted Instrument, Shares Issued \| shares									3,179,608
Required principal amount in percentage									25.00%
2022 Notes \| Fundamental Change
Debt Instrument [Line Items]
Percentage repurchase price									100.00%
2022 Notes \| Coupon Make-Whole Payments
Debt Instrument [Line Items]
Conversion of convertible debt to common stock									$ 4,900,000
Debt Conversion, Converted Instrument, Shares Issued \| shares									2,957,775
2022 Notes \| Make-Whole Fundamental Change \| Maximum
Debt Instrument [Line Items]
Conversion Rate									202.0202
2022 Notes \| Provisional Redemption
Debt Instrument [Line Items]
Number of consecutive trading days required for redemption										30 days
Excess to percentage of conversion price										150.00%
Number of trading days required for redemption										20 or more trading days
Loan Agreement
Debt Instrument [Line Items]
Debt instrument maturity date						Mar. 15, 2017
Proceeds from issuance of common stock and common stock units							5,100,000
End-of-term payment associated with loan							$ 1,000,000			$ 1,000,000
Loan Agreement \| Term Loans
Debt Instrument [Line Items]
Line of credit, maximum borrowing capacity						$ 31,100,000
Loan Agreement \| Term Loans \| First Installment
Debt Instrument [Line Items]
Line Of Credit Facility Current Borrowing Capacity						22,800,000
Debt, discount						1,600,000
Debt issuance cost						$ 1,500,000
Loan Agreement \| Original Agri-Energy Loan Agreement
Debt Instrument [Line Items]
Outstanding principal amount of term loan														$ 12,500,000
Restructure Period \| Amended Agri Energy Loan Agreement
Debt Instrument [Line Items]
Percentage of convertible senior notes embedded derivatives									13.00%
2014 Amendments
Debt Instrument [Line Items]
Debt instrument maturity date									May 31, 2017
Secured debt									$ 800,000

Schedule of Estimated Fair Value Assumption of Term Loan and 2017 Notes (Detail)	12 Months Ended
	Dec. 31, 2014 $ / shares	Aug. 31, 2014 $ / shares	Dec. 31, 2013 $ / shares	Jul. 31, 2012 $ / shares	Feb. 14, 2011 $ / shares
Debt Instrument [Line Items]
Stock price		$ 0.60	$ 1.35	$ 4.95	$ 15.00
Convertible 2017 Notes
Debt Instrument [Line Items]
Conversion Rate	0.8633
Maturity date	Mar. 15, 2017
Convertible 2017 Notes \| Term Loans
Debt Instrument [Line Items]
Stock price	$ 0.34
Conversion Rate	863.3
Conversion Price	$ 1.16
Maturity date	Mar. 15, 2017
Risk-free interest rate	0.80%
Estimated stock volatility	85.00%
Estimated credit spread	15.00%

Information Pertaining to Term Loan and 2017 Notes (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2014 USD ($)
Debt Instrument [Line Items]
Balance - December 31, 2014	$ 25,460
Change in Estimated Fair Value
Debt Instrument [Line Items]
Gain from change in fair value of debt	(648)
Balance - December 31, 2014	(648)
Convertible 2017 Notes
Debt Instrument [Line Items]
Exchange of Term Loan for 2017 Notes	25,907
Accrued paid in kind interest	201
Balance - December 31, 2014	26,108
Term Loan And 2017 Notes
Debt Instrument [Line Items]
Issuance of Term Loan	25,907
Accrued paid in kind interest	201
Gain from change in fair value of debt	(648)
Balance - December 31, 2014	25,460
Principal Amount of Term Loans
Debt Instrument [Line Items]
Issuance of Term Loan	25,907
Exchange of Term Loan for 2017 Notes	(25,907)
Principal Amount of Term Loans \| Convertible 2017 Notes
Debt Instrument [Line Items]
Accrued paid in kind interest	200
Balance - December 31, 2014	$ 25,500

Secured Debt Included in Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Less current portion of debt	$ (288)	$ (788)
Long-term portion of debt	485	9,339
TriplePoint Capital LLC
Debt Instrument [Line Items]
Secured debt	822	11,069
Less: Unamortized debt discounts	(49)	(942)
Secured debt, net	773	10,127
Less current portion of debt	(288)	(788)
Long-term portion of debt	485	9,339
TriplePoint Capital LLC \| TriplePoint - September 2010 Advance
Debt Instrument [Line Items]
Secured debt		917
TriplePoint Capital LLC \| TriplePoint - October 2011 Advance
Debt Instrument [Line Items]
Secured debt		6,657
TriplePoint Capital LLC \| TriplePoint - January 2012 Advance
Debt Instrument [Line Items]
Secured debt		$ 3,495
TriplePoint Capital LLC \| TriplePoint - Matures May 2017
Debt Instrument [Line Items]
Secured debt	$ 822

Information Pertaining to 2022 Notes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Beginning balance	$ 14,501	$ 25,554
Amortization of debt discount	2,648	3,300
Write-off of debt discount associated with conversion of debt		11,277
Gain from change in fair value of embedded derivative of the 2022 Notes	(3,470)	(3,114)	$ (17,000)
Conversion		(22,516)
Ending balance	13,679	14,501	25,554
Embedded Derivative Financial Instruments
Debt Instrument [Line Items]
Beginning balance	3,470	11,000
Gain from change in fair value of embedded derivative of the 2022 Notes	(3,470)	(3,114)
Conversion		(4,416)
Ending balance		3,470	11,000
Principal Amount of Convertible Notes
Debt Instrument [Line Items]
Beginning balance	26,900	45,000
Conversion		(18,100)
Ending balance	26,900	26,900	45,000
Debt Discount
Debt Instrument [Line Items]
Beginning balance	(15,869)	(30,446)
Amortization of debt discount	2,648	3,300
Write-off of debt discount associated with conversion of debt		11,277
Ending balance	$ (13,221)	$ (15,869)	$ (30,446)

Obligations by Year Relating to Secured Debt and Convertible Notes (Detail) $ in Thousands	Dec. 31, 2014 USD ($)
Disclosure Obligations By Year Relating To Secured Debt And Convertible Notes [Abstract]
2015	$ 319
2016	348
2017	26,263
2019 and thereafter	26,900
Total	$ 53,830

Capital Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended		12 Months Ended
	Feb. 14, 2011	Aug. 31, 2014	Jul. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stockholders Equity [Line Items]
Common stock, shares authorized				250,000,000	250,000,000
Preferred stock, shares authorized				10,000,000	10,000,000
Common stock, voting rights				The holders of the Company’s common stock have one vote per share.
Voting power required for amendment or repeal of any provisions				66.67%
Common stock shares issued and sold	8,222,500	30,000,000	12,500,000		21,303,750
Stock price	$ 15.00	$ 0.60	$ 4.95		$ 1.35
Net proceed from common stock issued		$ 16,400			$ 26,400
Proceeds from issuance of common stock and common stock warrants	$ 110,400	$ 2,400	$ 57,400	$ 18,000	28,761	$ 61,875
Number of shares of common stock exercisable for warrants		0.5		388,411
Issuance of common stock warrants				$ 2,400	$ 4,048
Purchase Price					$ 1.18
Fair value Adjustment					$ 200
Convertible Preferred Stock
Stockholders Equity [Line Items]
Issuance of Series C preferred stock converted from promissory notes and accrued interest (in shares)	16,329,703
Common Stock Warrants
Stockholders Equity [Line Items]
Issuance of Series C preferred stock converted from promissory notes and accrued interest (in shares)	398,032

Warrants to Purchase Shares of Common Stock Outstanding (Detail)	12 Months Ended
	Dec. 31, 2014 $ / shares shares
Class Of Warrant Or Right [Line Items]
Outstanding \| shares	37,563,548
Warrant , Exercise Price \| $ / shares	$ 1.18
Common Stock Warrants \| Warrant 1
Class Of Warrant Or Right [Line Items]
Issue Date	Dec. 31, 2013
Warrants expiration date	Dec. 31, 2018
Outstanding \| shares	21,303,550
Warrant , Exercise Price \| $ / shares	$ 1.43
Common Stock Warrants \| Warrant 2
Class Of Warrant Or Right [Line Items]
Issue Date	Aug. 31, 2014
Warrants expiration date	Aug. 31, 2019
Outstanding \| shares	15,000,000
Warrant , Exercise Price \| $ / shares	$ 0.85
CDP Gevo, LLC
Class Of Warrant Or Right [Line Items]
Issue Date	Sep. 30, 2009
Warrants expiration date	Sep. 30, 2016
Outstanding \| shares	812,771
Warrant , Exercise Price \| $ / shares	$ 2.70
TriplePoint Capital LLC \| Warrant 1
Class Of Warrant Or Right [Line Items]
Issue Date	Aug. 31, 2010
Warrants expiration date	Aug. 31, 2017
Outstanding \| shares	199,999
Warrant , Exercise Price \| $ / shares	$ 1.18
TriplePoint Capital LLC \| Warrant 2
Class Of Warrant Or Right [Line Items]
Issue Date	Oct. 31, 2011
Warrants expiration date	Oct. 31, 2018
Outstanding \| shares	157,035
Warrant , Exercise Price \| $ / shares	$ 1.18
TriplePoint Capital LLC \| Warrant 3
Class Of Warrant Or Right [Line Items]
Issue Date	Jan. 31, 2012
Warrants expiration date	Oct. 31, 2018
Outstanding \| shares	31,407
Warrant , Exercise Price \| $ / shares	$ 1.18
Genesis Select
Class Of Warrant Or Right [Line Items]
Issue Date	Jun. 30, 2013
Warrants expiration date	Jun. 30, 2018
Outstanding \| shares	30,000
Warrant , Exercise Price \| $ / shares	$ 1.63
Virgin Green Fund I, L.P.
Class Of Warrant Or Right [Line Items]
Issue Date	Jan. 31, 2008
Warrants expiration date	Feb. 29, 2016
Outstanding \| shares	28,786
Warrant , Exercise Price \| $ / shares	$ 5.48

Equity Incentive Plans - Additional Information (Detail) - shares	1 Months Ended	12 Months Ended
	Feb. 28, 2011	Dec. 31, 2014
Omnibus Securities and Incentive Plan 2006
Equity Incentive Plan [Line Items]
Common stock reserved for issuance		1,612,589
Stock Incentive Plan 2010
Equity Incentive Plan [Line Items]
Common stock reserved for issuance		1,957,844
Stock option grant, expiry period from grant date	10 years
Common stock, available for grant		1,481,824
Employee Stock Purchase Plan
Equity Incentive Plan [Line Items]
Common stock reserved for issuance		1,285,643
Common stock, available for grant		1,150,939
Share price as percentage of fair market value		85.00%

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Non-cash stock-based compensation	$ 2,860	$ 3,911	$ 7,979
Stock-based compensation	2,860	3,911	8,943
Non Cash
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Non-cash stock-based compensation	2,860	3,911	7,979
Non Cash \| Stock options and ESPP awards \| Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Non-cash stock-based compensation	303	640	808
Non Cash \| Stock options and ESPP awards \| Selling, General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Non-cash stock-based compensation	837	1,837	2,628
Non Cash \| Unvested restricted common stock \| Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Non-cash stock-based compensation	487	14	328
Non Cash \| Unvested restricted common stock \| Selling, General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Non-cash stock-based compensation	$ 1,233	1,381	1,599
Non Cash \| Warrants Issued \| Selling, General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Non-cash stock-based compensation		$ 39	2,616
Cash Based
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation			964
Cash Based \| Modified Stock Option Awards \| Selling, General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation			890
Cash Based \| Purchase Of Interest \| Selling, General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation			$ 74

Weighted-Average Assumptions Used to Estimate Fair Values for Stock Options Granted Using Black-Scholes Option Pricing Model (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rate	1.74%	1.26%	1.17%
Expected volatility factor	71.13%	71.96%	78.86%
Expected option life (in years)	5 years 5 months 12 days	5 years 9 months 18 days	5 years 9 months 11 days
Weighted average grant date fair value	$ 0.89	$ 1.18	$ 4.74

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option, estimated forfeiture rate	0.00%
Stock option, estimated forfeiture rate	5.00%
Total intrinsic value of options exercised	$ 0.0	$ 0.2	$ 2.2
Unrecognized compensation cost	$ 1.2
Unrecognized compensation cost, recognition period	2 years
Unvested restricted common stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost	$ 1.4
Unrecognized compensation cost, recognition period	2 years
Fair Value of Restricted Stock Vested	$ 1.5	$ 1.5	$ 0.9
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock awards vesting period	3 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock awards vesting period	6 years

Stock Option Award Activity (Detail) - USD ($)	12 Months Ended
Stock Option Award Activity (Detail) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Number of options
Options outstanding at beginning of year	2,871,563
Granted	1,128,536
Canceled or forfeited	(470,686)
Exercised	(5,000)
Options outstanding at end of year	3,524,413	2,871,563
Options exercisable	2,532,633
Options vested and expected to vest	3,519,749
Weighted Average Exercise Price
Options outstanding at beginning of year	$ 5.15
Granted	1.40
Canceled or forfeited	6.90
Exercised	0.47
Options outstanding at end of year	3.72	$ 5.15
Options exercisable	4.54
Options vested and expected to vest	$ 3.72
WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM
Options outstanding	5 years 7 months 10 days	6 years 6 months 26 days
Options exercisable	5 years 1 month 28 days
Options vested and expected to vest	5 years 7 months 10 days
AGGREGATE INTRINSIC VALUE
Options outstanding		$ 478

Summary of Information Associated with Outstanding and Exercisable Stock Options (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Options Outstanding, Number of Options	3,524,413	2,871,563
Options Outstanding, Weighted- Average Exercise Price	$ 3.72	$ 5.15
Options Outstanding, Weighted- Average Remaining Contractual Life in Years	5 years 7 months 10 days	6 years 6 months 26 days
Options Exercisable, Number of Options	2,532,633
Options Exercisable, Weighted- Average Exercise Price	$ 4.54
Options Exercisable, Weighted- Average Remaining Contractual Life in Years	5 years 1 month 28 days
Range One
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range	$ 0.46
Range of Exercise Prices, Upper Range	$ 0.49
Options Outstanding, Number of Options	377,533
Options Outstanding, Weighted- Average Exercise Price	$ 0.46
Options Outstanding, Weighted- Average Remaining Contractual Life in Years	2 years 4 months 6 days
Options Exercisable, Number of Options	377,533
Options Exercisable, Weighted- Average Exercise Price	$ 0.46
Options Exercisable, Weighted- Average Remaining Contractual Life in Years	2 years 4 months 6 days
Range Two
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range	$ 0.50
Range of Exercise Prices, Upper Range	$ 0.99
Options Outstanding, Number of Options	76,030
Options Outstanding, Weighted- Average Exercise Price	$ 0.88
Options Outstanding, Weighted- Average Remaining Contractual Life in Years	9 years 5 months 23 days
Options Exercisable, Number of Options	12,700
Options Exercisable, Weighted- Average Exercise Price	$ 0.88
Options Exercisable, Weighted- Average Remaining Contractual Life in Years	9 years 5 months 16 days
Range Three
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range	$ 1.00
Range of Exercise Prices, Upper Range	$ 1.89
Options Outstanding, Number of Options	1,847,752
Options Outstanding, Weighted- Average Exercise Price	$ 1.48
Options Outstanding, Weighted- Average Remaining Contractual Life in Years	7 years 6 months 7 days
Options Exercisable, Number of Options	948,553
Options Exercisable, Weighted- Average Exercise Price	$ 1.43
Options Exercisable, Weighted- Average Remaining Contractual Life in Years	6 years 1 month 17 days
Range Four
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range	$ 2.70
Range of Exercise Prices, Upper Range	$ 8.73
Options Outstanding, Number of Options	582,590
Options Outstanding, Weighted- Average Exercise Price	$ 2.88
Options Outstanding, Weighted- Average Remaining Contractual Life in Years	5 years
Options Exercisable, Number of Options	567,502
Options Exercisable, Weighted- Average Exercise Price	$ 2.87
Options Exercisable, Weighted- Average Remaining Contractual Life in Years	4 years 11 months 9 days
Range Five
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range	$ 9.41
Range of Exercise Prices, Upper Range	$ 9.57
Options Outstanding, Number of Options	210,466
Options Outstanding, Weighted- Average Exercise Price	$ 9.41
Options Outstanding, Weighted- Average Remaining Contractual Life in Years	6 years 6 months 18 days
Options Exercisable, Number of Options	196,303
Options Exercisable, Weighted- Average Exercise Price	$ 9.41
Options Exercisable, Weighted- Average Remaining Contractual Life in Years	6 years 6 months 4 days
Range Six
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range	$ 9.57
Range of Exercise Prices, Upper Range	$ 12.67
Options Outstanding, Number of Options	354,906
Options Outstanding, Weighted- Average Exercise Price	$ 10.40
Options Outstanding, Weighted- Average Remaining Contractual Life in Years	4 years 8 months 23 days
Options Exercisable, Number of Options	354,906
Options Exercisable, Weighted- Average Exercise Price	$ 10.40
Options Exercisable, Weighted- Average Remaining Contractual Life in Years	4 years 8 months 23 days
Range Seven
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range	$ 14.81
Range of Exercise Prices, Upper Range	$ 19.14
Options Outstanding, Number of Options	224,262
Options Outstanding, Weighted- Average Exercise Price	$ 17.17
Options Outstanding, Weighted- Average Remaining Contractual Life in Years	5 years 6 months 29 days
Options Exercisable, Number of Options	224,262
Options Exercisable, Weighted- Average Exercise Price	$ 17.27
Options Exercisable, Weighted- Average Remaining Contractual Life in Years	5 years 6 months 29 days

Non-Vested Restricted Stock Awards and Changes Period (Detail) - Unvested restricted common stock	12 Months Ended
	Dec. 31, 2014 $ / shares shares
Number of shares
Non-vested at December 31, 2013 \| shares	791,389
Granted \| shares	1,138,081
Vested \| shares	(983,530)
Canceled or forfeited \| shares	(70,675)
Non-vested at December 31, 2014 \| shares	875,265
Weighted-Average Grant-Date Fair Value
Non-vested at December 31, 2013 \| $ / shares	$ 2.52
Granted \| $ / shares	0.69
Vested \| $ / shares	1.54
Canceled or forfeited \| $ / shares	1.83
Non-vested at December 31, 2014 \| $ / shares	$ 1.30

Significant Agreements - Additional Information (Detail)	1 Months Ended							12 Months Ended
	Sep. 30, 2013 Boe	May 31, 2013 Boe	Mar. 31, 2013 Boe shares	Sep. 30, 2012 Boe	Sep. 30, 2011 Boe	Aug. 31, 2011	Mar. 31, 2010 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2009 USD ($)
Parties To Contract [Line Items]
Production, barrels of oil Equivalents \| Boe	20,000		3,650
Hydrocarbon revenue								$ 3,949,000	$ 2,157,000	$ 650,000
Increase Decrease In Production Barrels Of Oil Equivalents \| Boe		12,500
Research and development expense								14,120,000	20,179,000	19,431,000
Maximum
Parties To Contract [Line Items]
Production, barrels of oil Equivalents \| Boe				45,000	11,000
Lanxess
Parties To Contract [Line Items]
Amount recorded for supply agreement								0
Mansfield
Parties To Contract [Line Items]
Amount recorded for supply agreement								0
Agreement term						5 years
C And N
Parties To Contract [Line Items]
Amount recorded for supply agreement								$ 0
Agreement term						3 years
Automatic Renewal Term						1 year
Ethanol Marketing Agreement with Subsidiary of Mansfield Oil Company
Parties To Contract [Line Items]
Terms of agreement								The ethanol purchase and marketing agreement with C&N was entered into in April 2009 and automatically renews for subsequent one-year terms unless either party terminates the agreement 60 days before the end of term.
Biojet Fuel
Parties To Contract [Line Items]
Hydrocarbon revenue								$ 2,000,000	1,900,000	600,000
Development and Commercialization Agreements with ICM Inc
Parties To Contract [Line Items]
Terms of agreement								In December 2011, the development agreement was amended to extend the term indefinitely. The development agreement, as amended, may be cancelled by either party with 30 days’ prior written notice.
Commercialization Agreement End Date						2018-10
Joint Research Development License and Commercialization Agreement with Coca-Cola Company
Parties To Contract [Line Items]
Revenue recognized under agreement								$ 0	$ 1,400,000	$ 1,200,000
Cargill License Agreement
Parties To Contract [Line Items]
Terms of agreement								The Company may terminate the license agreement at any time upon 90 days’ prior written notice. Unless terminated earlier, the license agreement remains in effect until the later of December 31, 2025 and the date that no licensed patent rights remain
Royalty expense								$ 4,300,000
Research and development expense							$ 2,000,000				$ 900,000
Common stock shares issued \| shares			250,000

Gevo Development - Additional Information (Detail) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2010 USD ($)	Dec. 31, 2014 USD ($) Securities $ / shares shares	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Aug. 31, 2014 shares
Class Of Stock [Line Items]
Equity ownership of wholly owned subsidiary		100.00%
Non-cash stock-based compensation		$ 2,860	$ 3,911	$ 7,979
Number of shares of common stock exercisable for warrants \| shares		388,411			0.5
Warrant , Exercise Price \| $ / shares		$ 1.18
Derivative warrant liability		$ 3,114	7,243
Intercompany loans, description		In addition, as of December 31, 2014, under the terms of the Amended Agri-Energy Loan Agreement with TriplePoint, as amended, subject to certain limited exceptions, Agri-Energy is only permitted to pay if the following conditions are satisfied: (i) the Retrofit of the Agri-Energy Facility is complete and the facility is producing commercial volumes of isobutanol, (ii) its net worth is greater than or equal to $10.0 million, and (iii) no event of default has occurred and is continuing under the agreement. No gain or loss was recognized by the Company upon the initial consolidation of Gevo Development.
CDP Gevo, LLC
Class Of Stock [Line Items]
Number of shares of common stock exercisable for warrants \| shares		858,000
Warrant , Exercise Price \| $ / shares		$ 2.70
Warrants expiration date		Sep. 30, 2016
Percentage of warrant shares vested	50.00%
Derivative warrant liability	$ 14,000
CDP Gevo, LLC \| Warrant Agreement
Class Of Stock [Line Items]
Non-cash stock-based compensation				2,600
CDP Gevo, LLC \| Warrants to purchase common stock
Class Of Stock [Line Items]
Remaining warrant shares vested period	2 years
Common Class B
Class Of Stock [Line Items]
Equity ownership of wholly owned subsidiary		100.00%
Common Class B \| CDP Gevo, LLC
Class Of Stock [Line Items]
Outstanding interest rate		10.00%
Gevo Development
Class Of Stock [Line Items]
Number of membership interests outstanding \| Securities		2
Consideration for exchange of class B interest		$ 1,100
Capital contribution to subsidiaries		26,500	$ 29,600	55,500
Gevo Development \| Common Class B
Class Of Stock [Line Items]
Non-cash stock-based compensation	$ 800
Gevo Development \| Common Class B \| Co Managing Directors
Class Of Stock [Line Items]
Non-cash stock-based compensation				$ 100
Agri-Energy Facility
Class Of Stock [Line Items]
Minimum net worth required under loan agreement		$ 10,000

Net Loss Incurred by Gevo Development (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Gevo Development
Related Party Transaction [Line Items]
Gevo Development Net Loss	$ (14,778)	$ (19,243)	$ (15,870)

Redfield Energy, LLC - Additional Information (Detail) - Redfield Boe in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2014 USD ($) Boe Person shares
Related Party Transaction [Line Items]
Redfield ethanol production facility \| Boe	50
Limited partners capital account units issued \| shares	100
Members in board of managers \| Person	11
Cost for retrofit of Redfield Facilities \| $	$ 0.4

Income Taxes - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2014 USD ($)
Income Taxes [Line Items]
Net operating loss carry forwards expiration	2034
Uncertain tax positions recognized	$ 0
Federal And State
Income Taxes [Line Items]
Net operating loss carryforwards	289,900
Federal Research And Development \| Federal Tax
Income Taxes [Line Items]
Net operating loss carryforwards	$ 6,000

Tax Effects of Temporary Differences that Give Rise to Net Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforwards	$ 115,870	$ 96,748
Research and other credits	6,047	5,502
Other temporary differences	(2,478)	2,768
Deferred tax assets - before valuation allowance	119,439	105,018
Valuation allowance	$ (119,439)	$ (105,018)

Reconciling Items from Income Tax Computed at Statutory Federal Rate (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Components Of Income Tax Expense Benefit Continuing Operations [Abstract]
Federal income tax at statutory rate	35.00%	35.00%	35.00%
State income taxes, net of federal benefits	4.50%	5.70%	6.20%
Research and other credits	(1.30%)	(2.20%)	0.00%
Permanent deductions	(2.20%)	(1.50%)	(2.50%)
Valuation allowance	(36.00%)	(37.00%)	(38.70%)
Effective tax rate	0.00%	0.00%	0.00%

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2012
Employee Benefit Plans [Line Items]
Eligibility requirement service period as per the 401(k) plan	3 months
Employer matching contribution percentage	100.00%
Plan vesting period	2 years
Matching contributions		$ 0.5
Maximum
Employee Benefit Plans [Line Items]
Eligible for matching employee compensation contribution, percentage	5.00%

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Commitments And Contingencies [Line Items]
Operating lease expiration period	2016-07
Corporate apartment lease term expiring period	12 months
Operating leases rent expense	$ 0.5	$ 0.6	$ 0.6
Accounts Payable and Accrued Liabilities
Schedule Of Commitments And Contingencies [Line Items]
Capital lease liabilities	0.1	0.1
Other Long-term Liabilities
Schedule Of Commitments And Contingencies [Line Items]
Capital lease obligation included in other non-current liabilities	$ 0.3	$ 0.4
Software License Arrangement
Schedule Of Commitments And Contingencies [Line Items]
Capital lease agreement	6 years

Future Minimum Payments Under Non-Cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2014 USD ($)
Disclosure Future Minimum Payments Under Non Cancelable Operating Leases [Abstract]
2015	$ 1,826
2016	1,308
2017	1,044
2018	1,044
2019 and thereafter	529
Total	5,751
2015	157
2016	162
2017	167
Total	486
2015	1,983
2016	1,470
2017	1,211
2018	1,044
2019 and thereafter	529
Total	$ 6,237

Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended		12 Months Ended
	Feb. 14, 2011	Aug. 31, 2014	Jul. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	May 31, 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Amortization period of interest expense				36 months
2017 notes recorded at fair value				$ 25,460
Common stock shares issued and sold	8,222,500	30,000,000	12,500,000		21,303,750
Derivative warrant liability fair value				3,114	$ 7,243
Estimated fair value of the embedded derivatives				$ 0	$ 3,500
Warrants Issued in 2013
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Common stock shares issued and sold					21,303,750
Derivative warrant liability fair value							$ 4,000
Warrants Issued in 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Common stock shares issued and sold		15,000,000
Convertible 2017 notes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Maturity date				Mar. 15, 2017
2017 notes recorded at fair value				$ 26,108
Convertible 2017 notes \| Term Loans
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Maturity date				Mar. 15, 2017
2017 notes recorded at fair value				$ 25,500
2022 Notes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Secured debt				$ 26,900
Amortization period of interest expense				5 years
Maturity date				Jul. 01, 2022
Percentage of convertible senior notes embedded derivatives			7.50%
2017 notes recorded at fair value				$ 19,400	$ 15,900
Two Thousand Fourteen Amendment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Secured debt				$ 1,000
Two Thousand Fourteen Amendment \| Secured Debt
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Amortization period of interest expense				36 months
Maturity date				May 31, 2017
Percentage of convertible senior notes embedded derivatives				9.00%
Fair Value, Inputs, Level 1 \| Warrants Issued in 2013
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative warrant liability fair value					7,200
Fair Value, Inputs, Level 2 \| Warrants Issued in 2013
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative warrant liability fair value				$ 1,400
Fair Value, Inputs, Level 2 \| Warrants Issued in 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative warrant liability fair value				1,700
Corn
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Write down inventory				$ 100	$ 800	$ 300

Estimate of Fair Value of Secured Debt Obligations (Detail) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
TriplePoint - May 2014 Advance \| Principal Balance
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument fair value	$ 822
TriplePoint - May 2014 Advance \| Change in Estimated Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument fair value	$ 773
TriplePoint - January 2012 Advance \| Principal Balance
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument fair value		$ 3,495
TriplePoint - January 2012 Advance \| Change in Estimated Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument fair value		3,079
TriplePoint - October 2011 Advance \| Principal Balance
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument fair value		6,657
TriplePoint - October 2011 Advance \| Change in Estimated Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument fair value		5,942
TriplePoint - September 2010 Advance \| Principal Balance
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument fair value		917
TriplePoint - September 2010 Advance \| Change in Estimated Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument fair value		$ 847

Information on Business Segments (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Revenues	$ 28,266	$ 8,224	$ 24,385
Loss from operations	(39,777)	(55,515)	(71,437)
Interest expense	12,024	9,301	6,338
Depreciation expense	4,880	3,393	3,313
Acquisitions of plant, property and equipment	4,894	9,806	52,432
Total assets	98,928	116,355
Operating Segments \| Gevo
Segment Reporting Information [Line Items]
Revenues	4,718	4,822	3,505
Loss from operations	(26,567)	(39,745)	(58,837)
Interest expense	10,446	5,815	3,051
Depreciation expense	937	1,160	1,200
Acquisitions of plant, property and equipment	116	591	2,204
Total assets	95,680	100,888
Operating Segments \| Gevo Development / Agri-Energy
Segment Reporting Information [Line Items]
Revenues	23,548	3,402	20,880
Loss from operations	(13,210)	(15,770)	(12,600)
Interest expense	1,578	3,486	3,287
Depreciation expense	3,943	2,233	2,113
Acquisitions of plant, property and equipment	4,778	9,215	$ 50,228
Total assets	49,961	65,281
Intercompany Eliminations
Segment Reporting Information [Line Items]
Total assets	$ (46,713)	$ (49,814)

Subsequent Events - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended		12 Months Ended
	Feb. 23, 2015	Feb. 03, 2015	Jun. 30, 2014	Feb. 14, 2011	Aug. 31, 2014	Jul. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Subsequent Event [Line Items]
Common stock shares issued and sold				8,222,500	30,000,000	12,500,000		21,303,750
Purchase Price								$ 1.18
Exercise price of common stock							$ 1.18
Proceeds from issuance of common stock and common stock warrants				$ 110,400	$ 2,400	$ 57,400	$ 18,000	$ 28,761	$ 61,875
NASDAQ listing minimum bid price requirement description			On June 30, 2014, the Company received a deficiency letter from the Listing Qualifications Department of The NASDAQ Stock Market, notifying it that, for the prior 30 consecutive business days, the closing bid price of the Company’s common stock was not maintained at the minimum required closing bid price of at least $1.00 per share as required for continued listing on the NASDAQ Global Market. As part of the Company’s efforts to regain compliance with this requirement, the listing of the Company’s common stock was transferred from the NASDAQ Global Market to the NASDAQ Capital Market effective January 5, 2015. The transfer of the listing of the Company’s common stock to the NASDAQ Capital Market is not expected to have any impact on the trading in its common stock, and its common stock continues to trade under the symbol “GEVO.”
Common stock minimum bid price			$ 1.00
Consecutive business period to maintain minimum bid closing price			30 days
Additional period allowed to regain compliance with listing qualifications							180 days
Minimum bid price per share required to regain compliance with listing qualifications							$ 1.00
Regain compliance with listing qualifications period end date							Jun. 29, 2015
Common Stock
Subsequent Event [Line Items]
Common stock shares issued and sold									12,500,000
Subsequent Event
Subsequent Event [Line Items]
Proceeds from issuance of common stock and common stock warrants		$ 6,700
Effect of reverse stock split	The Company’s common stock, by a ratio of not less than one-for-ten and not more than one-for-thirty at any time on or prior to June 27, 2015
Subsequent Event \| Common Stock
Subsequent Event [Line Items]
Common stock shares issued and sold		33,250,000
Purchase Price		$ 0.20
Subsequent Event \| Series A Warrant
Subsequent Event [Line Items]
Exercise price of common stock		$ 0.27
Warrants expiration date		Feb. 03, 2020
Subsequent Event \| Series B Warrant
Subsequent Event [Line Items]
Exercise price of common stock		$ 0.20
Warrants expiration date		Aug. 03, 2015